The PhRMA Foundation
Awards in Excellence Gala

The “Awards in Excellence Gala” was a first-class affair, attended by more than 400 folks from our industry, awardees and advisory committee members. The Gala was held in Philadelphia, Pennsylvania during Interphex ’98—an exhibition/conference which is attended by 10,000 folks mostly from PhRMA member companies. See pages 18-27 of this Annual Report for full details and photographs of this exciting premiere event.
The quality of health care world-wide depends in large measure on advances in drug therapy, including the discovery and development of new medicines. This requires a framework which would foster the broad range of research, as well as the measurement of outcomes. Therefore, it is to this end that the mission of the PhRMA Foundation is dedicated to enhancing public health through biomedical technology and scientific research. The result will be new and improved medicines to enhance the quality of life world-wide while containing the overall cost of health care, thus improving and promoting the impact of the research-intensive pharmaceutical industry.

This mission shall be accomplished by:

- Developing the careers of young scientists and researchers dedicated to improving quality of life through discoveries in biomedical technology, scientific research, and outcomes measurement. As a result, the valuable base of well-trained, quality scientists created by these newly developed careers would serve as a resource to meet the current workforce needs of the scientific and academic community, government, and the research-intensive pharmaceutical industry.

- Establishing an infrastructure of expertise in biomedical technology, scientific research and outcomes measurement to produce leaders in industry, academia and government for the purposes of training the educational and scientific leaders of tomorrow.

- Building alliances between industry and academia to augment the research activities of scientists within both arenas. The purpose of this alliance would be to forge and strengthen the continuum of basic and clinical research by identifying and developing important therapeutic outcomes and significant therapeutic technology leading to the “medicines of tomorrow.” This in turn, would serve to enhance clinical practice and foster the improvement of patient care in America.
In Memory

GEORGE H. HITCHINGS, JR., Ph.D.
(1905 - 1998)
"My father died after a prolonged illness when I was twelve years old. The deep impression made by this event turned my thoughts toward medicine," — George H. Hitchings, Jr., Ph.D., 1988 Nobel Prize winner, giving his motivation for entering the field of science. Dr. Hitchings died on February 27, 1998, at his home in Chapel Hill, North Carolina.

Along with Gertrude Elion, Ph.D., Dr. Hitchings was awarded the 1988 Nobel Prize for Medicine, for their pioneering role in developing drugs in the fight against leukemia and malaria and such viral infections as herpes and AIDS.

For the past twenty years, Dr. Hitchings had pursued his growing interests in philanthropy. He set standards for philanthropy in the Triangle area of North Carolina that are still having a tremendous impact on people's lives. His contributions in the way of program development for the Foundation during its infancy is remembered by many. His focus served to lay a firm platform for the PhRMA Foundation for years to come.

Dr. Hitchings received his bachelor’s degree (1927 - cum laude) and master’s degree (1928) in Chemistry from the University of Washington and a doctorate in biochemistry from Harvard in 1933. 1933 also marked the year he married the love of his life, Beverly Reimer. His career began with the Wellcome Research Laboratories in 1942. In 1975, he retired as Vice President from Burroughs-Wellcome—now Glaxo Wellcome—but continued to report to the lab well into the '90s.

Robert A. Ingram, Chairman, Chief Executive Officer and President of Glaxo Wellcome, and Secretary-Treasurer of the PhRMA Foundation says: "George Hitchings knew how to combine his brilliance with a fierce dedication to his science. As a result, he revolutionized the world of drug exploration and design. It was his work that led to the first effective treatments for childhood leukemia and made the first kidney transplants possible."

Looking back on his career, Dr. Hitchings once said, "My greatest satisfaction has come from knowing that our efforts helped to save lives and relieve suffering."

We are very pleased to dedicate this Annual Report to George H. Hitchings, Jr., Ph.D., in tribute to his foresight in facilitating the establishment of the PhRMA Foundation.
In Memory

KEITH FENTON KILLAM, JR.
(1927 - 1998)

PhRMA Foundation, Advisory Committee Member 1973 - 1998

To commemorate Dr. Killam’s strong commitment and dedication to the teaching of students, the family has asked that donations be made to:

The Keith F. Killam, Jr. Memorial Fund for Graduate Student Travel
American Society of Pharmacology and Experimental Therapeutics (ASPET)
9650 Rockville Pike, Bethesda, Maryland 20814-3995

or

The Keith F. Killiam, Jr. Research Fund for the Western Pharmacology Society
Please contact Dr. Roberto P. Rosenkranz, P.O. Box 8, Menlo Park, California 94026
On January 2, 1998, Keith Fenton Killam, Jr., Ph.D., suffered a fatal heart attack and we lost a good friend. He was 70 years old. Keith is survived by his beloved wife of 43 years, Eva and his four children and four grandchildren.

Dr. Killam was born on March 2, 1927 in Hollywood, Florida. In World War II he served in the Army Medical Detachment, 1340th area service unit and was a military rifle marksman receiving a meritorious unit award.

He attended Tufts College where he received a B.S. in Engineering in 1948. He received his Masters Degree in Pharmacology in 1953 and his Ph.D. in Pharmacology in 1954, both from the University of Illinois, Graduate Professional College. Dr. Killam was a postdoctoral fellow in the departments of Pharmacology and Anatomy at UCLA Medical Center at the Brain Research Institute from 1955 until 1958 and while there he was a Research Fellow for the National Institutes of Health from 1957 to 1958. He also was a professor of Pharmacology at Stanford University School of Medicine from 1958 to 1968.

In 1968, Dr. Killam was asked to join the faculty at University of California, Davis to open a new medical school at that campus. He was the founding chair of the Department of Pharmacology at the UCD School of Medicine and was instrumental in the development of that medical school. He served as Chairman of the Pharmacology Department from 1968 until 1983. During that time, he was also affiliated with the National Center for Primate Biology in Davis, California and acted as Associate Director and Interim Acting Director in 1968. Dr. Killam was also Chairperson of the Faculty for the School of Medicine from 1972 to 1973 and Chairperson for Division of Sciences Basic to Medicine from 1977 to 1978. Dr. Killam was Director of Medical Learning Resources from 1978 to 1981 and Associate Dean for Sciences Basic to Medicine from 1979 to 1981. He officially retired from the School of Medicine at University of California, Davis in July 1994.

During Dr. Killam’s career, he was active on many national and international committees and societies on Drug Abuse and other basic science research issues and was a founding member of the American College of Neuropsychopharmacology (ACNP), serving on its Council from 1973 until 1977.

One had only to talk with Keith Killam but a short time to detect his great enthusiasm for pharmacology, students and, most of all, his family. He served with dedication on the PhRMA Foundation’s Basic Pharmacology Advisory Committee since 1973. The Board, advisory committee members and all who count him their friend will miss him greatly.
Certain guidelines have been developed to promote the wise and proper use of the limited resources available to the PhRMA Foundation. The areas of interest which govern the distribution of funds are in support of fundamental research on drugs and programs for training personnel in basic and clinical pharmacology, toxicology, morphology, pharmaceutics, pharmacoeconomics and bioinformatics.

Throughout the year, programs have been supported and developed which provide the means of achieving the goals of the Foundation. Many worthwhile proposals have been submitted. It has been necessary to limit support to those which hold the highest promise of advancing the purposes of the Foundation.

Those areas not supported within the existing guidelines are:

1. Research on specific drugs, unless the drug is for an orphan disease. This exclusion is not meant to preclude support of projects which, of necessity use a number of drugs to establish a methodology or screening program of potential general applicability. It does exclude those efforts primarily aimed at learning more about specific drugs or classes of drugs.

2. Funds for construction. The Foundation is not unmindful of the needs and the tremendous pressures for private funds for construction projects. However, it is believed that the scientific community can be better served by channeling the Foundation’s available resources into other areas.

3. Funds for travel (except as otherwise indicated).

4. Funds to cover entertainment costs.

While Foundation support of research continues, such support is currently primarily available in programs such as the Research Starter Grants as discussed on page 49 and under the “Education and Training Programs” Section on page 30.

While meetings have never received a large portion of the support dollar, only in very exceptional circumstances will meetings receive support in the future.
<table>
<thead>
<tr>
<th>Table of Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mission Statement</td>
</tr>
<tr>
<td>Purpose</td>
</tr>
<tr>
<td>Report of the Chairman</td>
</tr>
<tr>
<td>Report of the President</td>
</tr>
<tr>
<td>Tracking Thirty-Three:</td>
</tr>
<tr>
<td>Activities of the PhRMA Foundation</td>
</tr>
<tr>
<td>in its Thirty-Third Year</td>
</tr>
<tr>
<td>Awards in Excellence</td>
</tr>
<tr>
<td>Education and Training Programs</td>
</tr>
<tr>
<td>Clinical Pharmacology</td>
</tr>
<tr>
<td>Basic Pharmacology</td>
</tr>
<tr>
<td>Bioinformatics</td>
</tr>
<tr>
<td>Pharmacology/Morphology</td>
</tr>
<tr>
<td>Pharmaceutics</td>
</tr>
<tr>
<td>Pharmacoeconomics</td>
</tr>
<tr>
<td>Research Starter Grants</td>
</tr>
<tr>
<td>Report of the Treasurer</td>
</tr>
<tr>
<td>Organization and Administration</td>
</tr>
<tr>
<td>Advisory Committees</td>
</tr>
<tr>
<td>Applications</td>
</tr>
<tr>
<td>Benefactors</td>
</tr>
<tr>
<td>Current Programs for 1999</td>
</tr>
</tbody>
</table>
It is my pleasure to report to you that the past year has been marked by growth, excellence and a seamless transition in leadership for the PhRMA Foundation. For the first time since 1993, our year-on-year contributions increased, enabling us to further advance the vital work of the Foundation by investing additional resources in the medicines of tomorrow. For the first time ever, the Foundation presented Awards in Excellence to scientists whose careers exemplify the spirit of innovation and dedication that underpin everything we do. And for the first time in many years, the Foundation had a new President and CEO, as Donna Moore very capably assumed this position following the retirement of Morry Bectel last summer.

The following pages summarize the accomplishments of the Foundation during this period and describe the organization and its ongoing programs. Let me call your attention to just a few highlights from the past year that I believe best represent the efforts of our staff, advisory committees and directors to strengthen the ties between the research-based pharmaceutical industry and the academic community, thereby, advancing public health, research and clinical practice.

**FIRST-EVER AWARDS IN EXCELLENCE**

The Foundation’s inaugural Awards in Excellence were presented on March 17 during a gala event in Philadelphia that coincided with the Interphex ’98 show, which was generously hosted by Reed/Elsevier. The recipients were: Ing K. Ho, Ph.D., University of Mississippi Medical Center; Perry V. Halushka, M.D., Ph.D., Medical University of South Carolina; Gary M. Mawe, Ph.D., College of Medicine, University of Vermont; and Vincent H. L. Lee, Ph.D., School of Pharmacy, University of Southern California. On behalf of the entire Board of Directors, let me once again congratulate these distinguished scientists. (Their work is described in the Tracking Thirty-Three section of this report.)

What’s so special about these awards is that they represent a completely new area of recognition for the Foundation’s scientific community: They honor both the career accomplishments of individual researchers as well as the universities in which they conduct their important work.
Even more importantly, the *Awards in Excellence*, which provide stipends totaling $8,000 per recipient, are given to scientists who previously received Foundation funds—funds intended to help them become leaders in research and education.

In a sense, the *Awards in Excellence* offer testimony to the fact that these scientists have delivered on the promise they showed early in their careers. The outstanding contribution each of these individuals has made to public health over the course of their careers also reinforces the value of the Foundation’s fellowships and research grants. If you think about it, every single award we make in any given year has the potential to be the “spark” that produces the next leader in academia, public health policy or the research-based pharmaceutical industry. For those of us on the Foundation Board and advisory committees who have long been looking for a way to measure the long-term impact of our awards programs, the 1998 *Awards in Excellence* recipients have given us a new level of confidence that we are making a real difference in shaping the future of health care.

**FUELING OUR EFFORTS**

Of course, the work done by the Foundation is only possible because of the generosity of so many PhRMA member companies. As Chairman of the Foundation’s Board of Directors, I express our most sincere appreciation to the research-based pharmaceutical companies whose vision for the future of medicine is broad enough to encompass the discoveries and advances that originate from outside the industry, and whose commitment to the future has led them to support the Foundation for more than three decades. The increased financial support we received during the past year certainly reflects an understanding that together the industry and the academic community can be a formidable force in advancing health-care research. On behalf of the Board, I also extend very sincere thanks to those PhRMA associates, as well as the PhRMA research and international affiliates, who have supported our programs in so many ways during the past year.

As I’ve stated many times, the heart of the Foundation really beats within the advisory committees. These teams of world-class scientists painstakingly review the many grant applications we receive each year and do their very best to allocate our limited resources as wisely as possible. I thank them for their dedication and for their commitment to excellence, as reflected in the fellowship and research award recipients profiled in this report.

I also must congratulate Donna Moore and her staff, who bring the vision and mission of the PhRMA Foundation to life in countless ways every day of the year.

And finally, I must extend my sincere thanks to the industry leaders who have served with me on the PhRMA Foundation Board of Directors for the past year. These individuals have given generously of their time and talents, and each has contributed to the success we’ve recorded during this year: Jan Leschly, Chief Executive Officer, SmithKline Beecham plc, and PhRMA Founda-
tion Vice Chairman; Robert A. Ingram, Chairman, Chief Executive Officer, and President of Glaxo Wellcome Inc., and PhRMA Foundation Secretary/Treasurer; Richard J. Markham, Chief Executive Officer of Hoechst Marion Roussel; Robert N. Wilson, Vice Chairman, Board of Directors, Johnson & Johnson; Wayne P. Yetter, President and Chief Executive Officer of Novartis Pharmaceuticals Corporation; Patrick J. Zenner, President and Chief Executive Officer of Hoffmann-La Roche Inc; and Alan F. Holmer, President of PhRMA, who serves ex officio.

Of course the real "stars" of this report are the young scientists whose work is outlined in the pages that follow. I hope you will take the time to read about the fellowships and research awards they have been given, so that you too can share in the pride and the excitement that I feel for the future of the PhRMA Foundation—and more importantly, the future of medicine. Who knows which of these young researchers will some day be the recipient of the Award in Excellence for a distinguished career in research or education.

Robert C. Black
Chairman of the Board of Directors
PhRMA Foundation
and
President
Zeneca Pharmaceuticals
It is my distinct privilege to address you in this, my first, President’s Report. As Bob Black has mentioned, this past year was a busy one for the Foundation and eventful for me! Not only did I step into the role as President and CEO of the PhRMA Foundation, but my husband and I adopted a little eight-year old boy from Estonia. He only has one kidney, but now he has a family with three brothers to nurture him. With the addition of Joseph to my family, I now have a higher stake in the innovations of our great pharmaceutical industry, and the work of the PhRMA Foundation as it relates to the medicines of tomorrow.

You see, the PhRMA Foundation, over the last 33 years has been supporting the young-in-career scientists and educators at U.S. schools of medicine, pharmacy and public health—nearly 2,400 now. Not only are these folks dedicated to research themselves, but they have touched literally thousands of other scientists and researchers who now are the lifeblood of our industry. A recent survey shows that 86% of those receiving Foundation awards are still in academia—teaching the teachers and teaching the “do’ers.” Our founding fathers knew what they were doing when they decided to invest in the careers of university scientists. It is the difference in giving a man a fish or teaching him to fish. Simply put, through the work of the Foundation—through the gift of training the teachers and the young-in-career scientists—the infrastructure for the future of U.S. R&D rests. So today—33 years later—we are still jumpstarting the careers of the next generation of scientists—awardee by awardee. I feel very honored to serve this superb Foundation during such a time as this.

Raymond V. Gilmartin, now Chairman of the PhRMA Board and Chairman, President and CEO of Merck, quoted a Columbia University study, in his Hatfield Lecture at Cornell University, “Success hinges on a country’s willingness to adopt certain national policies essential to success. Primary among them are public funding of basic biomedical research...” This is the business of the PhRMA Foundation—in the private sector. Over the years, the PhRMA Foundation’s mission has been to support biomedical research in basic and clinical pharmacology, toxicology and morphology. Later years saw the introduction of funding for the discipline of pharmaceutics. And, more recently, with increasing challenges to exhibit the “value” of pharmaceuticals and
patient outcomes research, the Foundation began a “Faculty Development Award in Pharmacoeconomics,” and another in “Bioinformatics” thus positioning the Foundation to develop the careers of future scientists in these vital arenas.

This past year, 37% of our awards went to basic research in pharmacology, 31% for clinical pharmacology, 8% toward pharmacology/morphology, 11% in pharmaceutics, and 13% in bioinformatics and pharmacoeconomics. Our total contributions last year were up by 7%, thwarting a previous downward trend of five years mostly due to consolidations within our industry. This past year, as Bob Black indicated, we began the Awards in Excellence to highlight the careers of great scientists who had received PhRMA Foundation funding earlier in their careers. I feel personal gratification because it is with these awards that we truly see the value of Foundation awards—the value of supporting these young-in-careers scientists, by encouraging them to go on to greatness in their science to the benefit of mankind.

Too, this past year, we began an association with Reed/Elsevier—the largest pharmaceutical publisher in the world. During their Interphex Exhibition/Conference, the PhRMA Foundation held a marvelous Gala—another first! In combination, the purpose of the Gala was to honor these stellar Award in Excellence scientists, to highlight their work and their universities, the work of the Foundation and to develop another avenue of revenue for the Foundation (see “Awards in Excellence Gala” under Tracking Thirty-Three). We believe this Gala provides additional opportunities for former awardees and others to give something back to the Foundation.

On a personal note, in 1997, we saw the retirement of Edward J. Cafruny, M.D., Ph.D., as Foundation Scientific Consultant—one of many positions he has held during his 33-year association with the Foundation. We will miss Ed’s very wise counsel but I take comfort in knowing that Ed will always be part of the PhRMA Foundation. With Ed’s retirement, I am very pleased to announce that William R. Darrow, M.D., Ph.D., currently Chairman of our Scientific Advisory Committee, has agreed to serve, in addition, as the Foundation’s new Chief Science Advisor. Dr. Darrow is Senior Medical Advisor at the Schering-Plough Research Institute, and we welcome him to his new role with the Foundation.

Please take a moment now to peruse “Tracking Thirty-Three” for further activities of this past year, such as our Annual Awardee Meeting, held February 18-19, 1998 at the Willard Hotel in Washington D.C. Many thanks go to those scientists and researchers who took time from their busy schedules to attend the meeting and the scientific sessions. Special accolades go to Raymond L. Woosley, M.D., Chairman of Medicine at Georgetown University School of Medicine for being our banquet speaker. Ray, a former awardee, has been a long-time friend of the Foundation. Another long-time friend of the Foundation is Carl C. Peck, M.D., Director of Georgetown’s Center for Drug Development Science and former head of CDER. We were very honored to have Dr. Peck as our Thomas E. Hanrahan Memorial Lecturer. An abstract of his
presentation, "Is There Such a Thing as Drug Development Science?" is printed in this report.

I would also like to take this opportunity to express my sincerest gratitude to the Foundation Board and especially Bob Black. Through an extremely demanding schedule, he has willingly and graciously served as Chairman of the PhRMA Foundation Board—for the past four years. He was Secretary-Treasurer of the Foundation two years before that. His mild-mannered and decisive leadership has been the rock which has sustained the direction of the Foundation. My sincerest thanks and gratitude to him for serving during this year of transition in the Office of the President! Two Board members in particular were instrumental in the success of the Awards in Excellence Gala—Pat Zenner and Alan Holmer. Both of these Board members delivered superb presentations at our Gala. The Foundation and I are particularly appreciative of their time and energies on behalf of the Foundation. My special thanks to all members of the Foundation Board who are dedicated to the future of the Foundation!

Allow me to also thank our world-class advisory committee members. As Bob mentioned, they are the heart of the Foundation’s programs. The Foundation is very grateful to these dedicated scientists for the many hours spent in selecting the best and the brightest and for continuously reviewing the future direction of the Foundation. They have positioned us well.

I take great pride in the accomplishments of this past year and I have great optimism for the future of the PhRMA Foundation—PhRMA’s centerpiece of philanthropy. And now, I am very proud to present to you in this Annual Report, our “hope for the future”—the PhRMA Foundation awardees.

Donna Moore
President
PhRMA Foundation
TWENTY-SEVENTH ANNUAL
AWARDEE MEETING

The twenty-seventh PhRMA Foundation Annual Awardee Meeting was held on February 18-19, 1998, at the historic Willard Intercontinental Hotel in Washington, D.C. Over the years, the PhRMA Foundation has brought together current and former awardees, staff and advisory committee members to provide a forum for interaction—observing current research and hearing scientific presentations in related areas. The meeting was well attended by more than 100 scientists who have the prestige of being called PhRMA Foundation Awardees.

The activities began with a banquet held on the evening of February 18 with Board members, as well as distinguished advisory committee members and staff. The Foundation was highly honored to have as its banquet speaker Raymond L. Woosley, M.D., Ph.D., Chairman, Department of Pharmacology, Georgetown University School of Medicine. Dr. Woosley is currently a Special Consultant for the FDA and a member of the Clinical Trials Review Committee for the National Heart Lung and Blood Institute. He received the Rawls-Palmer Award for his contributions to medicine by the American Society of Clinical
Pharmacology and Therapeutics and was selected by practicing physicians to be listed in the *Best Doctors in America*. The Foundation is very pleased to have Dr. Woosley in its Alumni of Awardees. He received a Clinical Pharmacology Unit Development Award in 1988.

Thirty scientific posters were presented on the morning of February 19. Our Poster Session gives the awardees a chance to share the research they have undertaken which has been supported by their PhRMA Foundation grants. Enthusiastic, in-depth discussions are held among former and current awardees and advisory committee members. This session has become one of the most important events sponsored by the Foundation in recent years. The encouragement and affirmation these “new” scientists receive by the mentoring of more established scientists cannot be measured. We are very grateful that every year these dedicated former awardees and advisory committee members take time from their busy schedules to nurture the next generation of scientists.
The Poster Session was followed by the Annual Awardee Meeting’s General Session, at which time the Foundation was honored to have as the Thomas E. Hanrahan Memorial Lecturer, Carl C. Peck, M.D., Professor of Pharmacology and Medicine and founding Director for the Center for Drug Development Science at Georgetown University Medical Center. A brief synopsis of Dr. Peck’s presentation, entitled “Is There Such a Thing as Drug Development Science?” follows:

Is There Such a Thing as “Drug Development Science?”
Carl C. Peck, M.D.
Center for Drug Development Science
Georgetown University Medical Center
Washington, D.C.

Is there such a thing as medical science? (just kidding...). That such a question is posed (is there such a thing as “drug development science?”) may reflect (a) curiosity as to whether the process of drug development is essentially empirical or based upon mechanistic science, and, or (b) specialization of modern medical and biological scientists at the cellular, sub-cellular, or molecular levels, leading to lack of awareness of the multidisciplinary, integrative perspective necessary to achieve drug development as defined below.

In fact, there is a definable scientific framework and domain of disciplines that are routinely employed in the evolution of new drugs. To be more precise, drug development comprises the scientific, regulatory, and social processes and procedures involved in transforming a therapeutic concept into a commercially available therapeutic product for patients. The “science” of drug development encompasses scientific methods and approaches for derivation of new knowledge and technology to support of selection and evaluation of therapeutic candidates. General disciplines that contribute to drug development science include chemistry, biology, toxicology, basic and clinical pharmacology, medicine, and biostatistics. In addition, regulatory standard setting mirrors scientific development via utilization of “regulatory sciences” that include toxicology, basic pharmacology and microbiology, chemistry and manufacturing, biopharmaceutics, clinical pharmacology, biostatistics, and medicine.

Drug development is in the midst of a rapid transition from largely empirical to a scientifically sound, mechanistic approach. The science of clinical pharmacology is playing a key role in this transition, aided significantly by advances in biological, computational and biostatistical sciences. Computer simulation of clinical trials represents the cutting edge of such developments in mechanistic drug development.

The Georgetown Center for Drug Development Science (CDDS) exists to advance the science and science methodologies of scientific drug development (especially clinical phases) towards greatly enhanced efficiency, informativeness, and economy of time and resources.
On the afternoon of February 19, subgroup sessions were held in order for second-year awardees to deliver progress reports on their research and for attendees to hear presentations in their particular disciplines from former awardees and Advisory Committee members.

Presenters at the Clinical Pharmacology Subgroup Session, moderated by Paul Calabresi, M.D., Professor and Chair Emeritus, School of Medicine, Brown University:

Terrence F. Blaschke, M.D., Professor of Medicine and Molecular Pharmacology, Division of Clinical Pharmacology, Stanford University School of Medicine, Stanford, California: Title, “Medicine in an Underdeveloped Nation”; Richard D. Huhn, M.D., Hematology Staff Fellow, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland: Title, “The Clinical Pharmacology of Recombinant Interleukin-10”; and Arthur J. Atkinson, Jr., M.D., Senior Advisor in Clinical Pharmacology, National Institutes of Health, Bethesda, Maryland: Title, “NIGMS and Clinical Pharmacology Today.”
Presenters at the Basic Pharmacology Subgroup Session, moderated by Irwin M. Weiner, M.D., Emeritus Professor and Former Dean of the College of Medicine at the State University of New York, HSC, Brooklyn:

E. Leong Way, Ph.D., Professor Emeritus, Department of Pharmacology, Schools of Medicine and Pharmacy, University of California, San Francisco, California: Title, “Chinese Traditional Medicine and Contemporary Pharmacology: Perspectives and Overview”; Claire M. Lathers, Ph.D., F.C.P., Chief Scientific Officer, Barr Laboratories, Inc., Pomona, New York: Title, “Cardiovascular Studies from NASA”; and Richard H. Kramer, Ph.D., Assistant Professor, Department of Molecular and Cell Pharmacology, University of Miami School of Medicine, Miami, Florida: Title, “Polymer-Linked Ligand Dimers: Rational Drug Design Based on Spanning Binding Sites on Target Proteins.”

Presenters at the Pharmacology/Morphology Subgroup Session, moderated by George A. Condouris, Ph.D., Professor and Former Chairman, Department of Pharmacology/Toxicology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey:

Holly Boettger-Tong, Ph.D., Instructor, Department of Obstetrics and Gynecology, Baylor University College of Medicine, Houston, Texas: Title, “The Molecular Genetics of Male Infertility”; and G. Allen Nickols, Ph.D., Science Fellow, Monsanto/Searle, Chicago, Illinois: Title, “Angiogenesis Inhibition by AlphaV Beta3 Integrin Antagonists Limits Tumor Growth.”

Presenters at the Pharmaceutics Subgroup Session, moderated by James Swarbrick, D.Sc., Ph.D., Vice President Research and Development, AAI, Inc., Wilmington, North Carolina:

Sandy Koppenol, Ph.D., Postdoctoral Fellow, Department of Bioengineering, University of Washington, Seattle, Washington: Title, “Effect of Streptavidin-Biotin Dissociation Kinetics on the Two-Dimensional Crystallization of Streptavidin”; Anthony J. Hickey, Ph.D., Associate Professor, Division of Pharmaceutics, University of North Carolina School of Pharmacy, Chapel Hill, North Carolina: Title, “Dynamic Properties of Pharmaceutical Aerosol Powders”; and Samuel H. Yalkowsky, Ph.D., Professor of Pharmaceutical Sciences, University of Arizona College of Pharmacy, Tucson, Arizona: Title, “Ocular Delivery of Insulin.”

Dr. Lawrence K. Ng, University of Colorado, discusses his research with Matthew Murawski, R.Ph., Ph.D., Assistant Professor, University of Mississippi. Dr. Murawski is a recipient of a 1997 Faculty Award in Pharmacoeconomics.
FOUNDATION BOARD SETS THE COURSE

On May 11, Mr. Robert C. Black, Chairman of the PhRMA Foundation Board, called to order the Spring meeting of the Board, held during the PhRMA Annual Meeting at The Greenbrier, White Sulphur Springs, West Virginia.

This year—1998—marks the 33rd year that gentlemen of the PhRMA Board have given of their time and talents to serve as Foundation Board members, guiding and setting the course for future years. The Foundation, and the awardees, give special thanks to these sagacious men, who in spite of tremendous demands on their time, are joining in the Foundation’s vision and who have rededicated their efforts to fulfilling its mission. Officers elected for 1998-99 are: Mr. Robert C. Black, President, Zeneca Pharmaceuticals; Mr. Jan Leschly, Chief Executive Officer, SmithKline Beecham; and Mr. Robert A. Ingram, Chairman, President, and Chief Executive Officer, Glaxo Wellcome.

Bob Black, very graciously, has been our Chairman for four years and Secretary/Treasurer for two years before that. Jan Leschly came on the Board in 1992 and in this last year, very kindly stepped into the role as Vice-Chairman. Thanks to Bob Ingram, too, who became Secretary/Treasurer in 1997 after serving on the Board since 1994. Many thanks to the other Board members: Mr. Richard J. Markham, Chief Executive Officer, Hoechst Marion Roussel (since 1997); Mr. Robert N. Wilson, Vice Chairman, Board of Directors, Johnson & Johnson (since 1993); Mr. Wayne P. Yetter, President and Chief Executive Officer, Novartis Pharmaceuticals (since 1997); Mr. Patrick J. Zenner, President and Chief Executive Officer, Hoffmann-La Roche Inc. (since 1993); and PhRMA President Alan E. Holmer (Ex-Officio) (since 1996).
NEW FOUNDATION "AWARDS IN EXCELLENCE": FOUR SCIENTISTS HONORED AT INAUGURAL GALA IN PHILADELPHIA

In 1998, through the recommendation of the Scientific Advisory Committee and the backing of the Board, the Foundation enthusiastically developed a new program to recognize former Foundation awardees who, through their contributions to biomedical and pharmaceutical science, have exhibited excellence in their careers and fulfilled the goals of the PhRMA Foundation mission. That mission is "to enhance public health through biomedical technology and scientific research." The Awards in Excellence are thus provided to recognize both the career accomplishments of awardees and the stellar universities in which they conduct their important work.

NEW LEVEL OF FUNDING...

In the Fall of 1997, for the first time, letters were sent to Deans of Schools of Medicine, Pharmacy and Public Health asking for their recommendation for the Award in Excellence. When recommendations were received, four awards were selected—one in each area of clinical pharmacology, basic pharmacology, pharmaceutics and pharmacology/morphology. Then on March 17, 1998, in Philadel-
pha, Pennsylvania, the four awardees were honored with the award before an audience of 400 and presented with the award.

Donna Moore states, "I personally feel a sense of closure in that the Foundation has had a hand in furthering the careers of these scientists years ago and now we are recognizing them for the great scientists and educators they have become. It is as if we have come full circle." She added, "Also of great satisfaction to me is that through this process, we have developed a method of 'measuring' the impact of Foundation awards, not just to evaluate the programs, but also to be able to say to our benefactors, 'Here is what we have done. The vital work of the Foundation has made a difference for these scientists, and thus for our industry, academe, and government by helping to build the infrastructure of tomorrow's medicines awardee by awardee. In the end, the real winners will be the patients waiting for the cures.'

Thus, the Foundation, in part, serves as a catalyst for these scientists to the success of their mission in science and, through the generosity of the research-driven members of PhRMA, will continue to jumpstart the careers of future generations of scientists. These scientists will be the framework whereby tomorrow's medicines are developed.
VISIBILITY...

It has long been the goal of the Scientific Advisory Committee and the Board to enhance the visibility of the work of the Foundation. Aligning with Reed/Elsevier in this manner has certainly helped us attain that goal with communications in 15 of their publications and more than 600,000 pieces of literature reaching various facets of our industry.

ADDITIONAL REVENUE...

Reed/Elsevier has very kindly agreed to donate $20,000 to the work of the Foundation, and of course, contributions through those who participate in the Gala go to the Foundation.

THE INAUGURAL PHRMA FOUNDATION “AWARDS IN EXCELLENCE” GALA....

The “Awards in Excellence Gala” was a first-class affair, attended by more than 400 folks from our industry, awardees and advisory committee members. The Gala was held during Interphex ’98—an exhibition/conference which is attended by 10,000 folks mostly from PhRMA member companies. In short, this is an excellent opportunity for the PhRMA Foundation.
Thanks go to all who attended to take part in the spirit of the mission of the PhRMA Foundation (see attendee list under “Benefactors.”) Tables of ten were sold for $2,000 each (or $200 per seat). By participating in the evening’s events, for the first time, other former awardees were able to come along side the Foundation and, in part, give back to the Foundation what the Foundation had so long ago given to them.

Special thanks to two very special Board members who enriched the evening’s events with their presentations—Pat Zenner and Alan Holmer. By taking time from their busy schedules, these two gentlemen greatly enhanced events of the evening. Thanks go to all who attended the Gala for taking time to participate in and share in the recognition of the inaugural “Awards in Excellence.”

Our great appreciation goes to Reed/Elsevier for providing such an elegant forum and thanks to for providing the Foundation with $20,000 to assist with the awards. It was a grand event!

Special recognition and thanks to—Chris McCabe, Industry Vice President, and his lovely wife Christine who sang the Irish and American National Anthems; Mike Critzer, Director of Industry Development for Reed; and Anne Rodriguez—and the many others who pulled the Gala together.

Now, please join the Foundation in acknowledging the first recipients of the PhRMA Foundation “Awards in Excellence” and their universities:
Dr. Ing. K. Ho has been professor and Chairman of the Department of Pharmacology and Toxicology at the University of Mississippi Medical Center since 1982. He was recently appointed Interim Associate Vice Chancellor for Research and Graduate Studies at UMMC as well. His research has made enormous contributions to our knowledge of the neurochemical basis for tolerance to and physical dependence on barbiturates and opioids. He holds the Ph.D. degree from the University of California, San Francisco. Dr. Ho received the Faculty Development Award in Basic Pharmacology from the Pharmaceutical Manufacturers Association Foundation in 1974.

The University of Mississippi Medical Center in Jackson, Mississippi, is the University’s Health Sciences campus. Established in 1955, it houses Schools of Medicine, Nursing, Health Related Professions, and Dentistry; Graduate Programs in the Medical and Clinical Health Sciences; and the University Hospitals and Clinics with 623 beds.
Perry V. Halushka, M.D., Ph.D.
Professor of Pharmacology and Medicine,
Director, Division of Clinical Pharmacology,
Medical University of South Carolina

Perry V. Halushka, M.D., Ph.D., Professor of Pharmacology and Medicine, and Director, Division of Clinical Pharmacology, at the Medical University of South Carolina, was a recipient of the PhRMA Foundation Faculty Development Award in Clinical Pharmacology in 1975. His career has been marked by excellence in research, pre- and post-doctoral training, education and patient care. Dr. Halushka has published over 200 scientific articles in peer reviewed journals and written almost 50 invited reviews and book chapters. He is nationally and internationally known for his research on the role of thromboxane A2 (TXA2) and its receptors in physiologic and pathophysiologic processes, and for his studies of the characterization of human platelet and vascular TXA2 receptors. Dr. Halushka’s career exemplifies the quest of clinical pharmacology to span basic and clinical investigation.

Medical University of South Carolina: Since its beginning in 1824, the Medical University of South Carolina has grown from a small medical school, with the distinction of the first medical institution in the southern United States, to one of this country’s major academic medical centers. Its mission is patient care, research and education. Located on the Charleston peninsula, the university educates students from across the state and beyond in its colleges of Medicine, Nursing, Dental Medicine, Graduate Studies, Pharmacology and Health Professions as well as its residency programs. It also serves as a referral center for specialized care.
Pharmacology/Morphology

Gary M. Mawe, Ph.D.
Associate Professor, Department of Anatomy and Neurology,
University of Vermont, College of Medicine

Dr. Mawe received a 1985 PhRMA Foundation Pharmacology/
Morphology Fellowship and a 1988 Research Starter Grant at
Columbia University, College of Physicians and Surgeons. Dr.
Mawe received his doctorate in 1984 at the Ohio State University,
and was a postdoctoral fellow from 1984 to 1988 at the Columbia
University College of Physicians and Surgeons. He joined the
University of Vermont faculty in 1988. Dr. Mawe has developed an
internationally recognized research program which focuses on the
neural and hormonal control of the biliary tract. The work in
progress entails multidisciplinary histochemical and electrophysi­
ological approaches and has provided the first detailed cellular
examination of the biliary neurons and smooth muscle cells. This
research program focuses on mechanisms by which neurons in
gallbladder and sphincter of Oddi ganglions integrate neuronal,
hormonal and immune-mediated signals and how the output from
these neurons regulate organ function.

Columbia University is a leading higher education and research
institution. The College of Physicians and Surgeons is the oldest
medical school in America. It is one of the country’s outstanding
research institutions. It ranks number one in New York State and
number four nationally in federal research funding. Established in
1754, Columbia University has evolved into a major and renowned
higher education and research center in the United States.

The University of Vermont College of Medicine, established in
1822, is the nation’s seventh oldest medical school. The College
of Medicine excels at generating new knowledge through basic
science research and transferring new technologies to patient care.
The College is nationally and internationally recognized for
research activities, ranking in the top 20 percent of colleges of
medicine in terms of federal research grants per faculty member.
Vincent H.L. Lee, Ph.D.
Professor and Chairman,
Department of Pharmaceutical Sciences,
Professor of Ophthalmology, University of Southern California,
School of Pharmacy

Vincent H.L. Lee is Professor and Chairman of the Department of Pharmaceutical Sciences and Professor of Ophthalmology at the University of Southern California. A leading scientist in drug absorption mechanisms at the cellular and molecular levels, his research has laid a sound foundation for the next generation of delivery systems for drugs of synthesis and biotechnology. In addition to his scientific research, Lee also contributes to advancing pharmaceutical sciences through his editorship of peer-reviewed journals and through his presidency at the Controlled Release Society (1993) and the American Association of Pharmaceutical Scientists (1996).

University of Southern California: Founded in 1880, USC currently ranks among the top 10 private universities receiving federal funds for research and development support and in the top 20 among all universities. More than one-third of the incoming 1996 freshman class were honor students with SAT scores of 1200 or better. In 1996-97, 79 freshmen were National Merit Scholars. Since 1988, three USC students have been selected to attend Oxford University as Rhodes Scholars, while another was awarded a Marshall Scholarship.
ON THE WEB “WWW.PHRMAF.ORG”

The Foundation has a new face on the Web. If you have not “clicked” on our site recently, you are in for a surprise. Through this technology, the Foundation has been able to “streamline” its distribution of program information by allowing individuals to download their choice of data directly from the site, expediting the award process and saving time and money.

Also, through the site, we are able to acknowledge and honor our benefactors—the research-driven members of PhRMA, Associates and Research and International Affiliates. Without the generosity of these companies, the vital programs offered to Schools of Medicine, Pharmacy and Public Health would not be possible. The companies have given over $43 million since the inception of the Foundation.

Another major benefit of “the Web,” by the mere nature of the animal, is visibility. It has been a long-time goal of the Board and the Scientific Advisory Committee to bring more visibility to the good work of the Foundation. We are always seeking ways to highlight the work of our Foundation and benefactors—this web site goes long in accomplishing this goal.

We are very proud of our Web site and have plans in this next year to broaden it by highlighting the philanthropy of PhRMA member companies. In this manner, our goal is to honor the generous benefactors of the Foundation.

Please take time to visit our site.
On March 2, the American Association for the Advancement of Science (AAAS) and the Howard Hughes Medical Institute (HHMI) launched GrantsNet, a searchable online database (www.grantsnet.org) that provides up-to-date information on biomedical funding for scientists in the early stages of their careers. GrantsNet is a community resource involving funding organizations from all sectors of the biomedical community and is free to thousands of researchers who use it to search for funding opportunities each month. The PhRMA Foundation is enthusiastic about the project and information concerning the PhRMA Foundation fellowships has been entered into the GrantsNet collection system.

The Foundation is confident that being part of GrantsNet will help to fulfill our long-time goal of visibility. Also, the follow-up system in place through GrantsNet will produce valuable tracking information for committee members, Board members and awardees themselves regarding the Foundation grant programs.
The PhRMA Foundation’s primary mission is to promote the betterment of public health through scientific and medical research by providing funding to university-based scientists, researchers and educators. Foundation goals in education and research are accomplished through its twelve funding programs – three in clinical pharmacology, two in pharmacology/toxicology, one in the combined field of pharmacology-morphology, three in pharmaceutics, one in pharmacoeconomics, and one in bioinformatics. The Research Starter Grant provides starter funds in pharmacology, clinical pharmacology, drug toxicology and pharmaceutics. The Foundation also accepts applications in all program areas for research on drugs for rare diseases.
The clinical pharmacology program provides funding at three levels—students, postdocs, and faculty.

**FACULTY AWARDS IN CLINICAL PHARMACOLOGY**

The Foundation Faculty Development Awards in Clinical Pharmacology program makes three-year awards to medical schools for salary and fringe benefits in support of full-time junior faculty members. A ceiling of $40,000 has been set on the amount of Foundation participation in total yearly salary and fringe benefits for any candidate. With the awards beginning July 1, 1998, 111 individuals have been supported under this program since 1967.

**Recipients of the awards which began July 1998:**

**Nananda Francette Col, M.D., M.P.H.,** Assistant Professor of Medicine, Department of Medicine, Tufts University, School of Medicine (three years): “Hormone Replacement versus Alendronate Therapy for Postmenopausal Osteoporosis: Costs, Risks and Preferences.” Osteoporosis results in significant morbidity, mortality, and costs. Alendronate (Fosamax), a non-hormonal alternative to hormone replacement therapy (HRT) for the prevention and treatment of postmenopausal osteoporosis, is more effective than HRT in increasing bone density but lacks HRT’s carioprotective effects and cancer risks. Dr. Col has developed a decision model that estimates the impact of HRT on a woman’s life expectancy and lifetime risks of hip fracture, breast cancer, heart disease, based upon her personal risk factors for disease. Dr. Col is now seeking to 1) develop a decision support aid that combines patient-specific risk factors, costs, and preferences to help inform women and their physicians of the risks and benefits of HRT and alendronate by predicting their effects on longevity and lifetime risks of hip fracture, breast cancer, heart disease; 2) begin the development of an instrument to measure women’s individual preferences for health outcomes affected by HRT and alendronate, exploring their feelings about quality of life with osteoporotic fracture, coronary heart disease, breast cancer, and menopausal symptoms; and 3) determine the most effective ways to introduce this decision support tool into clinical practice to help clinicians counsel women on the risks and benefits of HRT vs. alendronate.

**William G. Haynes, M.D., M.B.Ch.B.,** Assistant Professor, Department of Internal Medicine, University of Iowa, College of Medicine (three years): “Vascular Effects of Homocysteine: Effect of Genetic Moderate Hyperhomocysteinemia on Endothelial Function (Protocols A-E).” Dr. Haynes’ research focuses on identifying and reversing the deleterious vascular effects of homocyst(e)ine. Homocysteine is an amino acid that is derived from metabolism of
methionine and whose catabolism is dependent on B-vitamin intake. Modest elevations in plasma homocyst(e)ine are associated with an increased risk of thrombotic and atherosclerotic disease, although a causative role for homocysteine in vascular disease has not been proven. Endothelial dysfunction is thought to contribute to atherosclerosis through promotion of platelet adhesion, blood coagulation, macrophage migration and mitogenesis. However, effects of homocysteine on endothelial function have not been addressed in humans. This research will test whether moderate hyperhomocyst(e)inemia causes endothelial dysfunction in humans and whether this occurs through increased oxidant stress. Endothelial function will be tested using intra-arterial administration of vasoactive agents and ultrasound-Doppler techniques. Subjects with genetic and environmental hyperhomocyst(e)inemia will be studied before and after normalization of plasma homocysteine concentrations by B-vitamin supplementation. Also, methionine loading and folate restriction will be used to experimentally induce hyperhomocyst(e)inemia in healthy subjects. In addition, Dr. Hayes will examine whether anti-oxidants reverse the effects of homocysteine on endothelial function. This research should provide valuable information on the endothelial actions of homocyst(e)ine and thus help to develop novel therapeutic approaches to the prevention of atherosclerosis.

Richard Z. Lin, M.D., M.P.H., Assistant Professor, Department of Pharmacology, University of Texas, San Antonio, School of Medicine (three years): "Sphingosine-1-phosphate Inhibits Vascular Smooth Muscle Cell Migration via p38 Mitogen Activated Protein Kinase." Vascular smooth muscle cell migration from the medial to within the intimal layer of the arterial wall is a key element in the development of atherosclerosis. A cell membrane lipid derivative, sphingosine-1-phosphate (SIP) inhibits vascular smooth muscle cell migration by unknown mechanisms. Dr. Lin has observed that SIP activates p38 mitogen activated protein kinase (MAPK) via a G-protein coupled signal transduction pathway in vascular smooth muscle cells. Dr. Lin proposes to investigate the mechanisms by which SIP activates p38 MAPK signaling pathway. His hypothesis is that SIP activates p38 MAPK using a signaling pathway mediated by G protein beta gamma subunits, a Rho family GTPase Cdc42 and its associated kinase, PAK1. He will express interfering mutants of these signaling molecules to determine if they are required for SIP to activate p38 MAPK. Dr. Lin will also use pharmacologic inhibitors and interfering mutants to determine if SIP requires activation of these signaling molecules to inhibit vascular smooth muscle cell migration. Understanding how SIP inhibits vascular smooth muscle cell migration has obvious clinical implications. Novel treatment strategies to suppress atherosclerotic lesions could be developed based on the cellular mechanisms used by SIP to inhibit vascular smooth muscle cell migration.
Entering their second year in 1998 are:

Craig W. Hendrix, M.D., Department of Medicine, The Johns Hopkins University School of Medicine: “Antiretroviral Pharmacodynamics in the Semen.”

Mark S. Wallace, M.D., Assistant Clinical Professor, Department of Anesthesiology, University of California, San Diego, School of Medicine: “Pharmacology of Human Experimental and Neuropathic Pain.”

Those awardees who entered the third year of their award in 1998 are:

Nabil S. Andrawis, Ph.D., M.D., Assistant Professor, Division of Clinical Pharmacology, Department of Medicine and Pharmacology, Georgetown University School of Medicine: “Endothelin-1 Regulation of Vascular Growth.”

Barbara D. Haehner, Ph.D., M.D., Clinical Lecturer, Department of Medicine, Indiana University, School of Medicine: “Investigation of the Bimodal Distribution of Cytochrome P450 3A5 (CYP3A5) Activity and Protein Content in Human Kidney.”

Awardees who ended their award in 1998 are:

James Francis Cleary, M.B., B.S., F.R.A.C.P., Research Associate/Clinical Instructor, Department of Human Oncology, University of Wisconsin - Madison, School of Medicine: “Therapeutics in the Treatment of Cancer Patients.”

Lionel David Lewis, M.B. Chir., M.R.C.P., M.D., Assistant Professor, Division of Clinical Pharmacology, Dartmouth Medical School: “Project 1: The relationship between mitochondrial DNA replication and the pancreatic toxicity of anti-HIV nucleoside analogs.”

Charles Michael Stein, M.B.Ch.B., M.R.C.P., Assistant Professor, Division of Clinical Pharmacology, Vanderbilt University School of Medicine: “Ethnicity and Vascular Reactivity.”
FELLOWSHIPS FOR CAREERS IN
CLINICAL PHARMACOLOGY

The second program in clinical pharmacology provides postdoctoral "Fellowships for Careers in Clinical Pharmacology." These fellowships offer clinicians an opportunity for intensive study in any of the basic sciences that fall within the general field of pharmacology. The program is open to physicians, dentists, and veterinarians who are well into their clinical training and wish to pursue careers in clinical pharmacology. With the year or two of support offered by this fellowship program, depending on the particulars of the undertaking, the individual can pursue full-time study in the basic pharmacologic sciences needed to complement his clinical skills.

The program allows an individual to apply for a fellowship three years in advance of the activation date of the award. For example, those applying for a fellowship in the fall of 1998 may request that the fellowship begin July 1999 or July 2000, or 2001.

First awards under this program were made in 1973. Since that time, 66 fellowships have been awarded.

Recipients who began their award in July 1998:

Jin Chen, M.D., Ph.D., Division of Clinical Pharmacology, Stanford University, School of Medicine (two years): "Role of Altered Transcription Factor CREB in Cellular Aging." Responsiveness to many drugs changes with human aging, which is likely due to change in expression of a variety of genes identified in senescent (aging) cells. Little is known about how gene expression is regulated in cellular senescence. Previous studies from Dr. Chen's laboratory have demonstrated that in aging fibroblasts cAMP production and cAMP-dependent protein kinase activity actually increased, but the capacity of cAMP to induce c-fos expression is markedly impaired. The blunted cAMP responses in aging cells are associated with decreased abundance and activity of an important transcription factor, CREB (cAMP responsive element binding protein). This protein binds to CRE (cAMP response element) in the promoters of many genes and is key in the stimulation of gene expression, suggesting that decreased expression of CREB may be rate-limiting for impaired downstream gene expression mediated by cAMP signal pathways during cell aging. To test this, Dr. Chen will use the normal human diploid fibroblast cell line (IMR-90) as a model system and overexpress CREB using an inducible expression system in the cells to manipulate cellular CREB levels to determine if overexpressed CREB restores normal and prevents impaired cAMP-mediated gene expression in senescent cells. CRE activity and CRE-dependent c-fos mRNA expression will be measured using a CRE-CAT reporter system and Northern blot analysis in response to cAMP-producing and PKA-activating drugs. Furthermore, the mechanisms for decreased expression of CREB gene in aging cells will be explored. This study will provide better understanding of the molecular mechanism of cell aging and the pharmacodynamic changes of drug action in aging at the level of gene regulation.
Luiza Cecilia Iancu, M.D., Division of Respiratory & Critical Care, Physiology & Medicine, Harbor-University of California, L.A. Research & Education Institute (two years): “mtDNA Mutations in Patients with Peripheral Arterial Disease.” Peripheral arterial disease is a common debilitating disorder which results most commonly from atherosclerotic occlusion of the arteries to the lower limbs in patients over the age of 40. These occlusions result in ischemia to the local tissue with impaired oxygen delivery to the muscle of the lower limbs. The therapeutic options for these patients are limited. Options consist of pharmacologic intervention, exercise and bypass surgery. Altered muscle metabolism represents a novel therapeutic target in this population. The current proposal is designed to test the hypothesis that peripheral arterial disease is associated with mtDNA damage, defective mitochondrial gene expression and abnormal mitochondrial function which contribute to the patients’ physiologic and functional status. By better understanding the molecular basis of this disease we hope to identify innovative strategies for therapeutic intervention and increase the options available for these patients.

Awarded who entered the second year of their award in 1998 are:

Gerald P. Linette, M.D., Ph.D., Harvard University, Massachusetts General Hospital: “Dendritic Cell Therapy of Human Malignant Melanoma.”

Spencer Z. Rosero, M.D., University of Rochester School of Medicine: “Gene-Specific Pharmaco-therapy in the Hereditary Long QT Syndrome Caused by the SCN5A Gene Mutation.”

Recipients who ended their award in 1998:

Karen C. Johnson, M.D., University of Virginia School of Medicine (One Year): “Clinical Trial Methodology in Stroke.”

**Basic Pharmacology**

**Faculty Development Awards in Basic Pharmacology**

Active for twenty-five years, the Faculty Development Award in Pharmacology has served to meet its goal to strengthen basic pharmacology by helping to maintain existing academic capability and, ultimately, expanding the field by enlarging the faculty base. To fulfill this goal, support has been provided, on a nationally competitive basis, to full-time junior faculty members who give promise of outstanding accomplishments.

The program provides stipend and fringe benefits of $30,000 per year for two years. To date the total number of awards made is 71.
Recipients of the 1998 Faculty Development Awards in Pharmacology which began July 1998 are:

Vladlen Z. Slepak, Ph.D., Assistant Professor, Department of Molecular & Cellular Pharmacology, University of Miami, School of Medicine (two years): “Investigation Signaling Pathway Mediated by a Novel G Protein β Subunit, Gβ5.” Hundreds of cell-surface receptors transduce external signals to the cell interior via heterotrimeric G proteins. G proteins are composed of multigene families of 20 α, 5 β and 11 γ subunits. This project investigates the signaling pathway mediated by the newest member of the Gβ subunit family Gβ5. This protein is of particular interest because it deviates significantly from the four previously known Gβ subunits in its amino acid sequence, physico-chemical properties, localization in cytosol and expression pattern (only in CNS). Although these unusual characteristics suggested that Gβ5 could be involved in a unique signaling process, previous in vitro analysis did not show major functional differences from the other Gβ subunits. In contrast, isolation of Gβ5 from its native source has revealed that in vivo it is coupled not to any of previously known Gα or Gγ subunits but rather to a pair of yet unidentified proteins with molecular weights of 65 and 10 kDa. This study will identify these proteins and investigate their possible functions, further unraveling this new signal transduction pathway. Identification of a specific set of receptors signaling through Gβ5 and its intracellular effectors will lead to finding new therapeutic targets in neuronal cells.

Stephanie Wengert Watts, Ph.D., Assistant Professor, Department of Pharmacology & Toxicology, Michigan State University (two years): “Vascular Tyrosine Kinase Activation in Hypertension; Interaction with Nitric Oxide.” In hypertension, the vasculature undergoes smooth muscle cell growth and an increase in sensitivity to contractile hormones. Both processes are dependent on tyrosine kinase activation. One pathway in specific, the mitogen activated protein kinase or MAPK pathway, plays a central role in growth and mitogenesis and is stimulated by both classical growth factors and agonist of G protein coupled receptors. Mitogen activated protein kinase or MAPK/Erk kinase (MEK) is a tyrosine kinase central to the MAPK pathway. One explanation for an increase in tyrosine kinase activity in hypertension is the loss of substance which inhibits the MAPK pathway. Nitric oxide (NO) is a vasoactive substance which decreases vascular smooth muscle tone and growth and endothelial-derived NO is decreased in some forms of hypertension. This project investigates the hypotheses that 1) stimulation of tyrosine kinase(s), in particular MEK, by agonists of G protein coupled receptors and growth factors in vascular contraction is augmented in hypertension; and 2) NO can inhibit MEK. The actions of serotonin, angiotensin II, the growth factor EGF and NO will be investigated using an integrated approach (MEK assays, isolated tissue bath, whole animal surgery).
Western analyses). These studies should reveal novel mechanisms of agonist-induced contraction in the vasculature and elucidate a manner by which vasoactive hormones, including growth factors, can affect vascular reactivity and growth. Moreover, these studies may demonstrate an increased activity in a pathway known to be important to growth and provide one mechanism by which this pathway becomes enhanced in hypertension (loss of NO).

Those individuals who began their awards in July of 1997 are:

John R. Hepler, Ph.D., Assistant Professor, Department of Pharmacology, Emory University School of Medicine: “The Gq Family of G Proteins: Functional Roles for Amino Terminal Diversity and Interactions with RGS Proteins.”

Brian K. Shoichet, Ph.D., Assistant Professor, Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School: “Structure-Based Inhibitor Discovery Against Beta-Lactamases.”

Ending their awards in 1998 are:

Richard H. Kramer, Ph.D., Assistant Professor, Department of Molecular and Cell Pharmacology, University of Miami, School of Medicine: “Probing the Structure and Function of Cyclic Nucleotide-gated Channels with Competitive Antagonists.”

Jia Bei Wang, M.D., Ph.D., Assistant Professor, Department of Pharmaceutical Sciences, University of Maryland at Baltimore, School of Pharmacy: “Studying the Relationships Between Structure and Function of the Opiate Receptors.”

FELLOWSHIPS FOR ADVANCED PREDOCTORAL TRAINING IN PHARMACOLOGY/TOXICOLOGY

One of the most popular awards is the PhRMA Foundation “Advanced Predoctoral Training in Pharmacology or Toxicology” fellowship program. The goal of this award is to increase the number of well-trained investigators in the field of pharmacological research. This program is designed to encourage and support promising students during their thesis research and is aimed at those candidates who are within two years of completing their research for pharmacology/toxicology doctoral dissertations.

This fellowship program provides a stipend of $12,000 a year and $500 a year for incidentals directly associated with preparation of the dissertation. The program, in its 21st year, has awarded a total of 247 fellowships.
Those who have been awarded 1998 fellowships beginning between January and July are:

**Alexander F. Hoffman,** University of Colorado, School of Medicine (two years): “Functional Studies of Somatodendritic Regulation of Dopamine in the Rat Substania Nigra.” The loss of dopamine regulation in the nigrostriatal pathway of the central nervous system has been linked to movement disorders, such as Parkinson's disease. This research is designed to investigate dopamine regulation within the nigrostriatal pathway, with special emphasis on release and reuptake mechanisms. In particular, these studies will explore the dynamics of dopamine release and reuptake from the cell bodies of the substantia nigra, and compare these processes with those observed in the striatum.

**Matthew Hoffmann,** Rutgers University, College of Pharmacy (two years): “The Role of the Proto-oncogenes, c-myc, c-myc, and c-fos in the Abnormal Myeloid Differentiation Induced by Hydroquinone.” Chronic exposure to benzene, a ubiquitous environmental pollutant, increases the risk of acute myelogenous leukemia (AML) in humans. Hydroquinone (HQ) a metabolite of benzene, causes altered differentiation in cultured myeloblasts similar to that observed in AML. This study plans to determine if HQ causes aberrant proto-oncogene expression in these myeloblasts leading to an altered differentiation pathway.

**Lloyd T. Lam,** University of Wisconsin-Madison, School of Medicine (two years): “Identification and Characterization of HS2NF5, a Novel Regulator of the Human Beta-Globin Locus Control Region.” The human beta-globin locus control region (LCR) is a powerful genetic element that regulates transcription of the beta-globin genes. Mr. Lam’s focus has been on one of the regulatory proteins, HS2NF5, that functions through the LCR. The LCR is an important model for long-range transcriptional activation and also may be useful for developing gene therapy approaches to the treatment of globin synthesis disorders.

**John C. Marquis,** Harvard University, School of Public Health (one year): “Defense Responses to Nitric Oxide in Human Cells.” Nitric Oxide (NO) is a biologically generated free radical that serves diverse roles in mammalian cell signaling and cytotoxicity. In view of the potential for cellular toxicity and mutagenesis upon exposure to NO, Mr. Marquis is studying genes and proteins which are induced in human cells exposed to NO, which may contribute to a defense response.

**Robert L. McFeters,** Cornell University, School of Veterinary Medicine (two years): “Structural Effects of C-terminal GluR-6 Post-translational Modification.” The goal of this project is to determine the solution structure of the intra-cellular domain of the glutamate receptor kainate sub-family subunit GluR-6 and how phosphorylation and palmitoilation at various sites affect the structural and dynamic properties of the protein.
Michelle Nelson, Stanford University, School of Medicine (two years): “Functional Studies of Xnekl, a Potential Cell-Cycle Regulatory Kinase in Xenopus Laevis.” Ms. Nelson is identifying key proteins that trigger cell division. Her project focuses on the Xnekl protein, which is structurally related to a protein (NIMA) known to be important for cell division in a filamentous fungus. She will determine whether Xnekl plays a similar role in regulating cell division in animal cells.

Timothy P. Reilly, Wayne State University, School of Pharmacy (one year): “Mechanism of Sulfonamide-Induced Adverse Drug Reactions in AIDS Patients.” Although trimethoprim-sulfamethoxazole is the most efficacious agent for the prophylaxis/treatment of *Pneumocystis carinii* pneumonia in AIDS patients, its use is significantly limited by an association with a high frequency of adverse effects. This poses a serious therapeutic dilemma in the treatment of AIDS patients since a large number of individuals are unable to continue therapy with the most effective antipneumocystis agent. This research will test the hypothesis that the increased incidence of adverse effects in HIV-infected individuals is secondary to the formation of neoantigens which may lead to an immune response.

Michelle Steffen, University of Tennessee, Memphis, School of Medicine (two years): “Hormonal Regulation of Carnitine Palmitoyltransferase I Gene Expression.” In thyroid disorders and insulin dependent diabetes (IDDM), accelerated oxidation of long chain fatty acids results in ketoacidosis. The mitochondrial enzyme carnitine palmitoyl-transferase I (CPT I) controls the rate of fatty acid oxidation and ketone body generation. This research will investigate the regulation of CPT I gene expression in diabetes and hyperthyroidism.

Michael Tanowitz, University of Virginia, School of Medicine (two years): “Role of SHP-2 in ARIA-induced Acetylcholine Receptor Gene Expression.” The specialized area of skeletal muscle known as the neuromuscular junction is an integral component of nerve-induced muscle contraction. Tyrosine phosphorylation plays an important role in the formation of the neuromuscular junction. This research will investigate the involvement of protein tyrosine phosphatases (enzymes that remove phosphate from tyrosine-phosphorylated proteins) in this event.

Phillip L. Thornton, Wake Forest University, Bowman Gray School of Medicine (one and one-half years): “Interaction of IGF-I and GABA<sub>6</sub> Receptors on Memory of Aged Animals.” The GABA<sub>6</sub> receptor has been demonstrated to be an important component of long-term potentiation, a process necessary for learning and memory. This project will investigate: (1) whether changes in expression or activity of GABA<sub>6</sub> receptors occur with age; (2) whether the anabolic hormone, IGF-I, modulates the GABA<sub>6</sub> receptor; and, (3) whether the age-related decline in IGF-I alters the GABA<sub>6</sub> receptor and thereby contributes to learning and memory deficits associated with age.
Bioinformatics

Faculty Development Awards in Bioinformatics

Begun in 1997, the Faculty Development Award in Bioinformatics seeks to build the infrastructure of expertise in the new science of Bioinformatics. As defined, Bioinformatics seeks to couple computer technology with the enormous amount of information currently stored in biological databases. It is a process whereby genomic sequence data is turned into molecular biology information for the purpose of benefiting mankind through drug discovery. Because of the shortage of trained scientists and faculty, the PhRMA Foundation is very pleased to offer for the second year this program.

Beginning their awards in July 1998:

Patricia C. Babbitt, Ph.D., Assistant Professor, Department of Biopharmaceutical Science, University of California, San Francisco, School of Pharmacy: “Understanding the Protein Universe Using Superfamily Analysis.” Dr. Babbitt is interested in the comparative study of related proteins to investigate structure/function relationships. The idea is that by understanding how nature has re-engineered proteins for new functions, we will be able to develop better strategies for re-engineering proteins in the laboratory, targeting proteins for drug development, and understanding the functions of specific proteins associated with genetic diseases. Using the huge volumes of data coming out of the genome projects, this approach provides a much more contextual picture of the structure-function paradigm than can be achieved by studying a single protein at a time. This work has been successfully applied to such problems as the prediction of function for unknown reading frames and elucidation of enzyme mechanisms. It has also provided new conceptual approaches for probing how differences in function can be generated from similar structural scaffolds. Major projects focus on superfamilies of enzymes whose member proteins perform a broad range of biochemical functions.
while sharing a common active site architecture. Recently, Dr. Babbitt’s laboratory has embarked on a project to develop and apply new tools in bioinformatics to identify very distant superfam­ily relationships across the entire protein universe.

Iosif Vaisman, Ph.D., Research Assistant Professor, Division of Pharmaceutics, University of North Carolina, Chapel Hill, School of Pharmacy (two years): “Computational Analysis of Protein Structure.” Revolutionary developments in computational biology, including both genomics and computational structural biology, lead to the rapidly increasing amount of data on biomolecular sequences and structures. The utilization of this data and the software for its processing will increase tremendously with the advent of the “postgenomic era” when biomedical and pharmaceutical research and clinical practice will incorporate sequence and structure analysis. Detailed knowledge of protein structure is essential for understanding the mechanisms of biological processes at molecular, cellular, and evolutionary levels. The primary goal of this proposal is to develop efficient techniques and algorithms for the analysis, classification and prediction of protein structures using computational geometry methods, and to develop a multidisciplinary bioinformatics program at the University of North Carolina.

Entering the second year of his award in 1998:

Mark Gerstein, Ph.D., Assistant Professor, Department of Molecular Biophysics and Biochemistry, Yale University, School of Medicine: “Analysis of Sequences and Structures on a Large Scale.”

PHARMACOLOGY/MORPHOLOGY

FELLOWSHIP AWARDS IN PHARMACOLOGY-MORPHOLOGY

The goals of this postdoctoral program are to increase our knowledge about the actions of drugs by direct study of their effects on cells and tissues, to correlate the morphological changes and, concurrently, to uncover associations observed with functional parameters of cells and tissues.

In order to be eligible for an award, the candidate must possess formal training in a morphologic specialty or in pharmacology. However, subsequent training in the complementary discipline, during the period of the fellowship, may be informal. On completion of the program, the fellow should be able to use the tools and concepts of both disciplines.

The awards are two years each. The level of support varies and is aimed at keeping within the existing stipends for similarly trained individuals within the applicant university. First offered in 1968, 102 awards have been made to date.
Recipients of the fellowship beginning July 1998 are:

Bonnie Lynn Firestein, Ph.D., University of California, San Francisco, School of Medicine (two years): “cGMP-Dependent Protein Kinase Regulation of Cell Number in Developing Trigeminal Ganglia.” Guanosine 3', 5'-cyclic monophosphate (cGMP) is a messenger molecule that has been implicated in the regulation of proliferation. However, very little is known about the effector that cGMP binds to which activates cellular events that mediate this regulation. cGMP-dependent protein kinase (cGK) is thought to be a major mediator of the effects of intracellular cGMP. cGK type I (cGKI) is expressed at high levels in the sensory ganglia. Dr. Firestein’s experiments focus on the role of cGKI in the regulation of sensory cell number. The experiments make use of two systems - the chick embryo model, which affords easy administration of pharmacological agents, and an in vitro cell culture system. Using the in ovo system, the role of cGKI in developing sensory ganglia will be determined using pharmacological agents. Effects on proliferation, precursor cell number, and axon outgrowth will be determined in control and treated embryos. In addition, in vitro culturing of sensory neurons will be used to determine the mechanisms that underlie effects seen in ovo. These experiments will provide information on how cell growth and division in the nervous system may be regulated by cGKI and can give insight into potential ways to increase regeneration of central and peripheral neurons to alleviate sensory dysfunction.

Laura Beth Kozell, Ph.D., Oregon Health Science University, School of Medicine (two years): “The Effects of Cocaine on Glutamate Synapses.” The goals of this fellowship are to examine ultrastructural immunocytochemical changes associated with identified glutamate nerve terminals as a correlate to the development of behavioral sensitization to cocaine and to determine whether interactions between dopamine (DA) and glutamate (Glu) transmission are involved in the sensitization process. To achieve these goals, Dr. Kogell will administer cocaine to rodents in a paradigm that should consistently result in behavioral sensitization and assess behavioral sensitization prior to determining whether there are any changes in nerve terminal immunolabeling. To determine whether interactions between Glu and DA transmission are involved in sensitization, she will block the development of sensitization, either with selective receptor antagonists or with lesions of mesolimbic dopaminergic neurons and assess whether the density of glutamate nerve terminal labeling changes. The novel aspect of this research is the ability to correlate neuronal adaptations with changes in the locomotor response to cocaine. Dr. Kozell is interested in teaching and conducting research on the neurochemical basis of drug-seeking behavior, specifically on the long-term neuronal adaptations following drug use.
Those individuals entering the second year of their award in 1998 are:

Laurie S. Nadler, Ph.D., Ph.D., University of Washington, School of Medicine: “Targeting of Muscarinic Receptor Subtypes in Polarized Cells.”

Steven J. Ritter, Ph.D., The University of Texas Medical School at Houston: “Mechanism of Breast-Cancer Suppression by Retinoids.”

Those individuals ending their awards in 1998 are:

Colleen M. Burns, Ph.D., Vanderbilt University, School of Medicine (one year): “Functional Characterization of Edited Serotonin 2C Receptor Isoforms in the Mammalian Central Nervous System.”

Zhen-Ping Chen, M.D., Ph.D., University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School: “Anatomical Studies of Opioid Receptor Like-1 (ORL-1) Expression and Targeted Inactivation of the ORL-gene.”

Kirk Hillsley, Ph.D., University of Vermont, College of Medicine: “Mechanism of CCK’s Action in the Control of Sphincter of Oddi Junction.”

Annika B. Malmberg, Ph.D., University of California, San Francisco, School of Medicine: “Spinal Mechanisms of Nociceptive and Neuropathic Pain.”

PHARMACEUTICS

UNDERGRADUATE RESEARCH FELLOWSHIPS IN PHARMACEUTICS

The Undergraduate Research Fellowship program began in 1990 and is designed to encourage undergraduate students in pharmacy, chemistry, biology or a related discipline to pursue an advanced degree in pharmaceutics, thereby attempting to supplement the infrastructure of well-trained investigators in this important discipline. The Foundation’s plan to accomplish this goal is by providing support for the undergraduate student to participate in a meaningful research project with a motivated, inspiring and research-active pharmaceutics faculty member.

The pharmaceutics faculty member must apply for the award and, once selected, is provided with a one-year, $5,000 fellowship which the faculty member can provide to a qualified undergraduate of his or her choosing. Seven awards were made for 1997, bringing the total number of awards to 86.
Faculty and their undergraduate students who received fellowships between January and August 1998 are:

**Hayat Alkan-Onyuksel, Ph.D.,** Associate Professor, University of Illinois at Chicago, College of Pharmacy (one year).
**Student:** Bhavish Bodalia, "Interaction of Vasoactive Intestinal Peptide with Phospholipids." The goal of this research is to study the interaction of vasoactive intestinal peptide, VIP, with phospholipids. This interaction will be determined from the association of VIP with phospholipid monolayers and peptide conformation changes by circular dichroism studies. The results will help to explain the increased bioactivity of the peptide when administered in the presence of phospholipids, and may lead to the development of novel lipid based delivery systems for other peptide drugs similar in nature to VIP.

**William F. Elmquist, Pharm.D., Ph.D.,** Assistant Professor, University of Nebraska, College of Pharmacy (one year).
**Student:** Christine M. Brandquist, "Biochemical Characterization of the Expression of the Multidrug Resistance-Associated Protein in the Blood-Brain Barrier." The overall goal of this research will be to characterize the expression and function of the multidrug resistance-associated protein (MRP) in the central nervous system (CNS). It is important to study the function of MRP in the blood-brain barrier to avoid potentially harmful drug interactions when substrates and inhibitors of MRP are used in combination. Moreover, an understanding of the role MRP plays in limiting drug delivery to the brain will enable the design of therapeutic strategies to enhance the brain delivery of compounds to treat diseases in the CNS.

**David J.W. Grant, D.Sc.,** Professor of Pharmaceutics, University of Minnesota, College of Pharmacy (one year).
**Student:** R. Todd Burkhardt, "Influence of the Water of Hydration on the Physico-Mechanical and Tableting Properties of a Model Pharmaceutical Hydrate." This research will probe the effects of structural water on tableting behavior by relating Hiestand's tableting indices of the well-characterized solid phases of the model compound L-Lysine Monohydrochloride, to the interactions of water in the crystal structure.

**James N. Herron, Ph.D.,** Associate Professor, University of Utah, College of Pharmacy (one year).
**Student:** Justin LeClaire, "Affinity and Avidity of Antibodies as Targeting Moieties in Immunoliposomes." An immunoliposome is a specialized drug-delivery system that consists of a sub-micron sized lipid vesicle (which contains a payload of cytotoxic drug) and pendant antibody molecules (which target the vesicle to pathological tissue such as tumors). This research investigates how to formulate immunoliposomes for optimal targeting of pathological cells.
Vincent H.L. Lee, Ph.D., Professor and Chairman, Department of Pharmaceutical Sciences, University of Southern California, School of Pharmacy (one year).

**Student: Robert Chen**, “Characterization of the Alveolar Organic Cation Transporter.” This research seeks to characterize the organic cation transporter in the lung for improving pulmonary drug absorption.

Jagdish Singh, Ph.D., Assistant Professor, North Dakota State University, College of Pharmacy (one year).

**Student: Angela K. Levang**, “Mechanism of Transdermal Transport Enhancement of Beta Blockers by Terpenes.” This research evaluates the effect of terpenes on the percutaneous absorption enhancement of beta blockers in order to develop non-invasive transdermal therapeutic systems to treat hypertension.

Philip C. Smith, Ph.D., Assistant Professor, University of North Carolina, School of Pharmacy (one year).

**Student: Rachel C. Turner**, “Drug Disposition in CF-Knockout Mice.” Drug disposition in children with cystic fibrosis (CF) is often unpredictably altered. We propose to evaluate whether CF Knockout mice are reliable models for this altered drug elimination by investigating the disposition of acetaminophen and ICG in this mouse model.

**FELLOWSHIP FOR ADVANCED PREDOCTORAL TRAINING IN PHARMACEUTICS**

Active for eleven years, this program assists awardees who have one or two years remaining in their pharmaceutics predoctoral training—the time during which they are engaged in dissertation research.

The fellowship program provides a stipend of $12,000 a year for two years and $500 a year for incidentals directly associated with the preparation of the dissertation. Five awards were made for 1997 bringing the total number of awards made to 66:

Those who received fellowships beginning between January and July 1998 are:

**Jinnian Gao**, University of Kansas, School of Pharmacy (two years): “Transport Characteristics of Peptidomimetics Containing Hydroxyethylamino Peptide Bond Bioisosteres.” This research is designed to examine the effects of the hydroxyethylamino peptide bond bioisosteres on the permeability properties of peptidomimetics across the Caco-2 cell monolayers. An emphasis will be on the influence of the P-glycoprotein related efflux systems and the di/tripeptide transporters on the transport of these peptidomimetics.
Susan Wells Hovorka, University of Kansas, School of Pharmacy (two years): "Effect of Protein Structure on the Metal-Catalyzed Oxidation of Growth Hormones." Metal-Catalyzed-Oxidation (MCO) compromises the efficacy and reliability of protein pharmaceuticals. Little is known about the mechanistic pathways of MCO degradation. The aim of this research is to elucidate such mechanisms by studying MCO of growth hormones as a function of solvent composition. Preliminary findings suggest that physical parameters of solvents may induce structural changes in the protein which protect the drug from MCO.

LaToya Shantel Jones, University of Colorado, School of Pharmacy (two years): "Mechanistic Determination of Stabilization of Pharmaceutical Proteins using Nonionic Surfactants." Pharmaceutical protein formulations are often stabilized by the addition of nonionic surfactants. The mechanisms of stabilization are not clear. Ms. Jones will investigate the stabilization of pharmaceutically important proteins by nonionic surfactants to elucidate these mechanisms.

Jeffrey J. Seyer, University of Iowa, College of Pharmacy (two years): "The Development of Near-Infrared Spectroscopy for Determining Crystallinity in Pharmaceutical Solids." Assessment of drug crystallinity is an important aspect in pharmaceutical product development. This research is aimed at the development of a non-invasive, non-destructive method for quantifying crystallinity in pharmaceutical solid products using near-infrared spectroscopy. A secondary objective of this work is to utilize near-infrared methods to examine process induced changes in solids in multi-component systems. The results obtained from near-infrared analysis will be compared to those from other solid-state characterization methods.
Timothy J. Spitzenberger, University of Nebraska, College of Pharmacy (two years): “Delivery of Protease Inhibitors to the Brain Utilizing Inhibitory Drugs of the Efflux P np P-Glycoprotein.” The treatment of human immuno-deficiency virus in the central nervous system is hampered by the limited delivery of protease inhibitors. This may be caused by the role the membrane efflux protein, p-glycoprotein, plays in the blood-brain barrier. The aim is to investigate the brain delivery of protease inhibitors through inhibition of p-glycoprotein.

POSTDOCTORAL RESEARCH FELLOWSHIPS IN PHARMACEUTICS

Complementing the other two pharmaceutics programs offered by the PhRMA Foundation, the Postdoctoral Research Fellowships in Pharmaceutics was initiated to encourage more qualified graduates to obtain the postdoctoral research training so vitally needed in the area of pharmaceutics. The PhRMA Foundation and its Pharmaceutics Advisory Committee recognize the critical need for such well-trained scientific investigators. The postdoctoral award gives $25,000 per year for two years. Since its inception, ten awards have been given.

Entering the second year of his award in 1998:

William G. Mallet, Ph.D., Cornell University Medical College: “The Intracellular Transport and Localization of TGN38/41.”

Ending her award in 1998:

Sandy Koppenol, Ph.D., University of Washington, School of Pharmacy. “Two Dimensional Protein Crystallization at Interfaces.”

PHARMACOECONOMICS

FACULTY DEVELOPMENT AWARDS IN PHARMACOECONOMICS

There is widespread concern about rising health care expenditures as well as increasing interest in understanding the impact of new therapies on patient-focused outcomes such as mortality, functional status, and quality of life. Because of these new perspectives, choices about new drugs are now based not only on traditional safety and efficacy measures but also on patient-assessed efficacy and economic values measures. A drug development program needs to include all of the outcome measures so that the information needs of the different decision makers can be met. Taking this into consideration, the PhRMA Foundation, recognizing the need for human resources to perform these
outcome analyses, has implemented its Faculty Development Awards in Pharmacoeconomics program. Each award offers $40,000 annually for two years. The program is now in its fourth year and has made one award for 1998:

Beginning his award in July 1998:

C. Daniel Mullins, Ph.D., Assistant Professor, University of Maryland, School of Pharmacy (two years): “Integration of Theory and Practice of Pharmacoeconomics by Disease State”. Dr. Mullins’ research focuses on the development of new methodologies for the economic evaluation of drug products, health care services and medical technologies. He feels the appropriate mechanism through which one can accomplish the goal of establishing more standardized pharmacoeconomic methodology is by focusing on individual disease states. The empirical research that he has performed in this area utilizes clinical trial and retrospective databases to perform pharmacoeconomic analyses aimed at evaluating “real world” cost-effectiveness. These studies can aid in the development of new assessment methods by tailoring general guidelines for pharmacoeconomic analysis to specific illnesses. Dr. Mullins has focused a considerable amount of time on the pharmacoeconomics of cardiovascular drugs and emergency medicine, but also work in the areas of infectious diseases, osteoarthritis, osteoporosis, and pneumonia. He is also interested in public policy issues that go beyond the micro level of assessment (drug vs. drug) into a systems-level analysis. Dr. Mullins is currently working with several managed care providers on research efforts that address disease state management issues. These research projects examine the relationship between optimal drug therapy, related services, health outcomes, and the total cost of care.

Entering the second year of their awards are:

John M. Brooks, Ph.D., Assistant Professor, College of Pharmacy, University of Iowa: “The Use of Instrumental Variable Techniques in Pharmacoeconomics Outcomes Research.”

Matthew M. Murawski, R.Ph., Ph.D., Assistant Professor, School of Pharmacy, University of Mississippi: “Development of a Pharmacoeconomic Center at The University of Mississippi.”

Those who ended their awards in 1998 are:

Karen Blumenschein, Pharm.D., Assistant Professor, College of Pharmacy, University of Kentucky: “Incorporating Quality of Life Assessments into Pharmacoeconomics Evaluations.”

A. Mark Fendrick, M.D., Assistant Professor, School of Medicine, University of Michigan: “Development of a Pharmacoeconomics Research and Education Program at the University of Michigan.”
RESEARCH GRANTS

One of the most important aspects of the PhRMA Foundation effort has been the support of fundamental research. In 1971 a change in emphasis within the Foundation shifted the bulk of the funds into educational support programs and, consequently, less into research. It is understood that these educational programs place high emphasis on the research programs of the applicants for each award. In this sense, educational support programs are in fact also supporting research. The Foundation continues to accept requests for research support and suggestions for pertinent research projects since it is important that the potential within the Foundation for helping that particularly promising effort be maintained.

ETHICAL CONSIDERATIONS

The Scientific Advisory Committee as well as the program advisory committees of the PhRMA Foundation are sensitive to the appropriate use of experimental subjects, animals and humans, in research. In their deliberations, they consider all aspects of a proposal and may deny support for many reasons. Careful consideration is given to humane use and care of animal subjects. For human and animal research, the project review committee requires, in writing, a statement of adherence to prevailing standards of ethical research practices, including Institutional Review Board approval before initiation of any research project. In addition, for human research, assurance of informed consent will be required.

RESEARCH STARTER GRANTS

Research Starter Grants are intended to provide financial support for beginning investigators. The program, in 1998, supported eight Research Starter Grants at $12,500 per year with the second year contingent upon need. The first awards were made in 1972, and a total of 508 grants have been made, including the eight awards beginning January 1, 1998.

Recipients of the Research Starter Grants which began January 1998:

Rama S. Dwivedi, Ph.D., Northwestern University, School of Medicine (two years): “Regulation of Adenosylmethionine (Adomet) Synthetase Gene Expression in Neuroblastoma Tumor Cells. A Potential Role in Drug Resistance.”

Linda A. Felton, Ph.D., University of New Mexico, College of Pharmacy (two years): “Influence of Additives in Aqueous Polymeric Dispersions on Film-Tablet Adhesion.”
Charles Giardina, Ph.D., University of Connecticut, School of Medicine (two years): "Nonsteroidal Anti-inflammatory Drugs, Short Chain Fatty Acids and TNF-induced Apoptosis of Colon Cancer Cells: Synergistic Effects and the Role of Reactive Oxygen."

Richard Z. Lin, M.D., University of Texas, Medical School at San Antonio (two years): "Sphingosine-1-phosphate Inhibits Vascular Smooth Muscle Cell Migration via p38 Mitogen Activated Protein Kinase."

Jose E. Manautou, Ph.D., University of Connecticut, School of Pharmacy (two years): "Regulation of Hepatic ATP-Dependent Transport Proteins and their Potential Role in the Hepatobiliary Secretion of Model Hepatotoxic Agents."

Lawrence Ka-yun Ng, Ph.D., University of Colorado, School of Pharmacy (two years): "A Study of Ultrasonic Mediation of the Transport of Therapeutic Agents Across the Blood-Brain Barrier."

Felicia V. Nowak, M.D., Ph.D., St. Louis University, School of Medicine (two years): "Preoptic Regulatory Factors as Growth Factors in the CNS: Regulation by Steroid Hormones."

Peter W. Swaan, Ph.,D., Ohio State University, School of Pharmacy (two years): "Molecular Specificity of the Intestinal Bile Acid Carrier."

Based on need for funds, a review of the nine research starter grantees whose awards began January 1, 1997, for a second year of the award resulted in six of them having their awards continued. Those who did not receive the second year should be congratulated on receiving further funding.

Robert L. Judd, Ph.D., Northeast Louisiana University School of Pharmacy: "Effect of Metformin on Phosphoenolpyruvate Carboxykinase Activity in Cultured Rat Hepatocytes and H4IIE Cells."

Patrick T. Murray, M.D., University of Chicago School of Medicine: "Mechanisms of Endotoxin Effect on Mesangial Calcium Mobilization."

Kathryn M. Partin, Ph.D., Colorado State University College of Veterinary Medicine: "Pharmacological Contributions of GluRB to Allosteric Modulation of AMPA Receptors."

Steven P. Schwendeman, Ph.D., Ohio State University College of Medicine: "Maintaining Protein Structure in Biodegradable Polymer Microspheres."

Zhao-Hui Song, Ph.D., Texas A&M University College of Medicine: "Characterization of Cannabinoid Receptors in the Eye."

Elizabeth Wattenberg, Ph.D., University of Minnesota Medical School: "cJun As a Target for TPA-type and Non-TPA-Type Tumor Promoters."
The PhRMA Foundation has been building the infrastructure for the future of biomedical and pharmaceutical science for the past 33 years. The vital work of the Foundation has been accomplished through the generosity of the research-intensive pharmaceutical manufacturers who are the members of PhRMA—associates and research affiliates. As I recap the finances of this prestigious Foundation for 1997, I would like to give special thanks to our benefactors who are listed in the back of this annual report.

The total income of the Foundation in 1997 was $2,289,157. Of this amount, $1,505,250 came from contributions; $469,476 came from interest and dividends; $61,484 was from realized gains on sales of securities; $221,896* was from unrealized gains on sale of securities; and $31,051 came from unexpended grant monies.

In 1997, grant expenditures totaled $1,511,152; Foundation Annual Awardee Meeting expenses amounted to $73,360; Advisory Committee Meetings and Travel was $61,725; Honoraria totaled $27,480; Publications and web site cost $47,951; Professional Services totaled $43,950; and office expenses for 1997 rent, salaries, taxes and trust commission totaled $393,300. The total net assets as of December 31, 1997 was $4,820,369. This figure, however, does not reflect the tentatively authorized, undisbursed funds for some of the grants and programs described earlier. The Foundation reports these amounts as expenditures when the funds are disbursed. As of December 31, 1997, the contingency liability for 1998-00 was $3,018,639.

The Foundation's financial position as of December 31, 1997, has been audited by the Rosslyn, Virginia accounting firm of Buchanan & Company.

Robert A. Ingram
Secretary-Treasurer
PhRMA Foundation

*FASB rules require that "unrealized gains on sales of securities" be reported as part of total income.
## Statement of Income and Expenditures
### For the Year Ended December 31, 1997

### Income:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$1,505,250</td>
</tr>
<tr>
<td>Interest and Dividends</td>
<td>469,476</td>
</tr>
<tr>
<td>Realized Gains on Sale of Securities</td>
<td>61,484</td>
</tr>
<tr>
<td>Unrealized Gains on Sale of Securities</td>
<td>221,896</td>
</tr>
<tr>
<td>Miscellaneous Income</td>
<td>31,051</td>
</tr>
</tbody>
</table>

**Total Income** $2,289,157

### Expenditures:

**Programs:**

- **Grants**—Note A
  - Clinical Pharmacology Unit Award $0
  - Faculty Awards in Clinical Pharmacology $279,750
  - Faculty Awards in Basic Pharmacology $120,000
  - Fellowships for Careers in Clinical Pharmacology $77,700
  - Advanced Predoctoral Fellowships in Pharmacology/Toxicology $225,000
  - Pharmacology-Morphology Fellowships $143,952
  - Medical Student Research Fellowships $10,000
  - Research Starter Grants $262,500
  - Advanced Predoctoral Fellowships in Pharmaceutics $118,500
  - Undergraduate Fellowships in Pharmaceutics $35,000
  - Postdoctoral Fellowships in Pharmaceutics $43,750
  - Faculty Development Award in Pharmacoeconomics $180,000
  - Faculty Development Award in Bioinformatics $15,000

**Subtotal—Grants** $1,511,152

- **Annual Awardee Meeting** $73,360
- **Program Total** $1,584,512

**Administrative**

- Committee Meetings and Travel $61,725

**Management and General:**

- Honoraria $27,480
- Publications $47,951
- Office Expense $46,216
- Professional Services $43,950
- Rent $26,800
- Salaries and Retirement Fund Contribution $312,544
- Taxes, Insurance and Depreciation $40,582
- Trust Commission Expense $6,304
- Loss on Sale of Equipment $7,070

**Administrative Total** $620,622

**Total Expenditures** $2,205,134

---

**Note A**—In addition to the amounts shown, the Foundation is committed, subject to annual review, to make certain grants. At December 31, 1997 the amounts still to be disbursed with respect to these grants amounted to aggregated $3,018,639 with $1,805,303 of this to be disbursed during 1998; $1,033,336 in 1999; $180,000 in 2000.

- Change in Net Assets $84,023
- Net Assets, January 1, 1997 $4,736,346
- Net Assets, December 31, 1997 $4,820,369
The PhRMA Foundation operates through its Officers, Board of Directors and six advisory committees. On May 11, 1998, Mr. Robert C. Black, President of Zeneca Pharmaceuticals, was re-elected Chairman for the fourth year. Mr. Jan Leschly, Chief Executive of SmithKline Beecham plc, was re-elected Vice Chairman, and Robert A. Ingram was re-elected Secretary-Treasurer.

Donna Moore was elected President and CEO beginning September 1, 1997. Maurice Q. Bectel, D.Sc., who has served the Foundation as President for twelve years, retired effective August 31, 1997. Mr. Bectel continues to serve as consultant to the Foundation. Edward J. Cafruny, M.D., Ph.D., who has been Foundation Scientific Consultant, and was instrumental in the development and vision of the Foundation, retired August 31, 1997.

Dr. Cafruny began his association with the Foundation by serving on the Scientific Advisory Committee beginning in 1968. He later became Chairman of the Basic Pharmacology Advisory Committee, then Consultant to the Foundation in 1989.

Stepping into a newly created post of Scientific Advisory is William R. Darrow, M.D. Dr. Darrow has served as Chairman of the Scientific Advisory Committee and continues in that capacity.

- Donna Moore, Dr.
- Carl C. Peck, William
- R. Darrow, and Dr.
- Paul Calabresi enjoy a few moments at the Annual Awardee Meeting General Session on February 19.
1998-99
OFFICERS

Robert C. Black
Chairman
PhRMA Foundation
President
Zeneca Pharmaceuticals
Wilmington, Delaware

Robert A. Ingram
Secretary-Treasurer
PhRMA Foundation
Chairman, Chief Executive
Officer and President
Glaxo Wellcome Inc.
Research Triangle Park, North
Carolina

Jan Leschly
Vice Chairman
PhRMA Foundation
Chief Executive
SmithKline Beecham
Philadelphia, Pennsylvania

Donna Moore
President
PhRMA Foundation
Washington, D.C.

Richard J. Markham
Chairman of the Board of
Management and
Chief Executive Officer
Hoechst Marion Roussel
Bridgewater, New Jersey

Wayne P. Yetter
President and Chief Executive
Officer
Novartis Pharmaceuticals
Corporation
East Hanover, New Jersey

1998-99
BOARD OF
DIRECTORS

54
Patrick J. Zenner  
President and Chief Executive Officer  
Hoffmann-La Roche Inc.  
Nutley, New Jersey

Robert N. Wilson  
Vice Chairman, Board of Directors  
Johnson & Johnson  
New Brunswick, New Jersey

Alan F. Holmer  
President  
Pharmaceutical Research and Manufacturers of America  
Washington, D.C.  
(Ex-Officio)

William R. Darrow, M.D., Ph.D.  
Chief Science Advisor  
PhRMA Foundation  
Senior Medical Advisor  
Schering-Plough Research Institute  
Schering-Plough Corporation  
Kenilworth, New Jersey

Maurice Q. Bectel, D.Sc.  
PhRMA Foundation Consultant
Advisory Committees

Scientific Advisory Committee

William R. Darrow, M.D., Ph.D.
(Chairman)
Senior Medical Advisor
Schering-Plough Research Institute
Schering-Plough Corporation
Kenilworth, New Jersey

Paul Calabresi, M.D.
Professor and Chair Emeritus
Department of Medicine
Brown University
Providence, Rhode Island

Jean Paul Gagnon, Ph.D.
Director of Industry Affairs
Hoechst Marion Roussel
Kansas City, Missouri

Michael D. Gershon, M.D.
Professor and Chairman
Department of Anatomy & Cell Biology
Columbia University
College of Physicians and Surgeons
New York, New York

Arthur Hull Hayes, Jr., M.D.
President
MediScience Associates
New Rochelle, New York

James Swarbrick, D.Sc., Ph.D.
Vice President
Research and Development
AAI Inc.
Wilmington, North Carolina

Hugh H. Tilson, M.D., Dr.P.H.
Senior Medical Advisor for Health Affairs
International Surveillance Epidemiology and Economics
Glaxo Wellcome Inc.
Research Triangle Park, North Carolina

Irwin M. Weiner, M.D.
Emeritus Professor and Former Dean
College of Medicine
State University of New York, Brooklyn
Health Science Center
Brooklyn, New York

Clinical Pharmacology Advisory Committee

Paul Calabresi, M.D.
(Chairman)
Professor and Chair Emeritus
Department of Medicine
Brown University
Providence, Rhode Island
Darrell R. Abernethy, M.D., Ph.D.
Francis Cabell Brown Professor of Medicine and Pharmacology
and Director
Division of Clinical Pharmacology
School of Medicine
Georgetown University
Washington, D.C.

Thorir D. Bjornsson, M.D., Ph.D.
Vice President, Clinical Pharmacology
Worldwide Clinical Research & Development
Bristol-Myers Squibb
Princeton, New Jersey

Terrence F. Blaschke, M.D.
Professor of Medicine and Molecular Pharmacology
Division of Clinical Pharmacology
Stanford University
School of Medicine
Stanford, California

Alan S. Nies, M.D.
Vice President
Clinical Sciences
Merck & Co., Inc.
Rahway, New Jersey

James W. Aiken, Ph.D.
Director of Experimental Biology
Pharmacia & Upjohn
Stockholm, Sweden

Terry L. Bowlin, Ph.D.
Vice President Research
Bio Chem Therapeutics
Laval, Quebec, Canada

Theodore M. Brody, Ph.D.
Professor and Former Chairman
Department of Pharmacology and Toxicology
Michigan State University
East Lansing, Michigan

George C. Fuller, Ph.D.
Dean and Professor of Pharmacology
College of Pharmacy and Allied Health Professions
Wayne State University
Detroit, Michigan

Paul S. Guth, Ph.D.
Professor of Pharmacology
School of Medicine
Tulane University
New Orleans, Louisiana

Keith F. Killam, Jr., Ph.D.
Professor and Former Chairman
Department of Medical Pharmacology
University of California, Davis
School of Medicine
Davis, California

George R. Lenz, Ph.D.
President
GRLEN and Associates
Andover, Massachusetts

Bernard L. Mirkin, M.D., Ph.D.
William G. Swartzchild, Jr. Distinguished Chair in Research
Head and Director of Research
Children's Memorial Institute for Education and Research
Professor of Pediatrics
Northwestern University Medical School
Chicago, Illinois

Irwin M. Weiner, M.D.
(Chairman)
Emeritus Professor and Former Dean
State University of New York
Brooklyn, New York

*B. L. Mirkin, M.D., Ph.D.
Sidney Pestka, M.D.
Professor and Chairman
Department of Molecular Genetics and Microbiology
University of Medicine & Dentistry of New Jersey
Robert Wood Johnson Medical School
Piscataway, New Jersey

Frederick M. Radzialowski, Ph.D.
President
FMR Research Associates
Glenview, Illinois

Michael D. Gershon, M.D.
(Chairman)
Professor and Chairman
Department of Anatomy & Cell Biology
Columbia University
College of Physicians & Surgeons
New York, New York

George A. Condouris, Ph.D.
Professor and Former Chairman
Department of Pharmacology
University of Medicine & Dentistry of New Jersey
Newark, New Jersey

Cheryl Dreyfus, Ph.D.
Professor
Department of Neuroscience & Cell Biology
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
Piscataway, New Jersey

Felix A. de la Iglesia, M.D.
Vice President
Pathology & Experimental Toxicology
Parke-Davis Pharmaceutical Research
Ann Arbor, Michigan

Robert B. Jennings, M.D.
James B. Duke Professor of Pathology
School of Medicine
Duke University
Durham, North Carolina

Hugh B. Lewis, B.V.M.S., M.R.C.V.S.
Senior Vice President Practice Development
Medical Management International, Inc.
Portland, Oregon

David L. Nelson, Ph.D.
Senior Research Scientist
Lilly Research Laboratories
A Division of Eli Lilly and Company
Indianapolis, Indiana

Henry J. Ralston III, M.D.
Professor and Chairman
Department of Anatomy
School of Medicine
University of California, San Francisco
San Francisco, California
James Swarbrick, D.Sc., Ph.D.  
(Chairman)  
Vice President  
Research & Development  
AAI Inc.  
Wilmington, North Carolina

William J. Curatolo, Ph.D.  
Assistant Director  
Pfizer Central Research  
Pfizer Inc.  
New York, New York

William I. Higuchi, Ph.D.  
Distinguished Professor and  
Chairman  
Department of Pharmaceutics  
College of Pharmacy  
University of Utah  
Salt Lake City, Utah

George Zografi, Ph.D.  
Professor of Pharmaceutics  
School of Pharmacy  
University of Wisconsin-Madison  
Madison, Wisconsin

Jean Paul Gagnon, Ph.D.  
(Chairman)  
Director of Industry Affairs  
Hoechst Marion Roussel  
Kansas City, Missouri

Lyle Bootman, Ph.D.  
Dean  
College of Pharmacy  
University of Arizona  
Tucson, Arizona

Jane T. Osterhaus, Ph.D.  
Director of the Arthritis Team  
Department of Global Health Outcomes  
Scarle  
Skokie, Illinois

Frederick W. Telling, Ph.D.  
Vice President  
Corporate Strategic Planning and Policy  
Pfizer Inc.  
New York, New York

---

Haian Fu, Ph.D., Assistant Professor, Emory University; James A. Weyhenmeyer, Ph.D., Professor, University of Illinois; and Dennis Paul, Ph.D., Associate Professor, Louisiana State University Medical Center enjoy the Annual Awardee Meeting reception. Dr. Ng received a 1993 Postdoctoral Fellowship in Pharmaceutics, a 1997 Undergraduate Research Fellowship in Pharmaceutics and a 1998 Research Starter Grant. Dr. Weyhenmeyer and Dr. Paul both received postdoctoral fellowships in Pharmacology and Morphology.
Descriptive brochures and application forms for all of the PhRMA Foundation grant programs are available on the World Wide Web: www.phrmaf.org. For more information, please write to:

Ms. Donna Moore
President
Pharmaceutical Research and Manufacturers
of America Foundation
1100 Fifteenth Street, N.W.
Washington, D.C. 20005
(202) 835-3470 (phone)
(202) 467-4823 (fax)

Joshua Aibla, M.D.,
University of California,
expounds on his poster
display during the Poster
Session on February 19,
1998 with Spencer
Rosero, M.D., University
of Rochester.

Terry Blaschke, M.D. and
his wife Jeannette.
Dr. Blaschke is a
former awardee and
a current member of
the PhRMA
Foundation’s
Clinical
Pharmacology
Advisory
Committee.
PHRMA MEMBER COMPANIES AND COMPANY FOUNDATIONS

OVER $3.5 MILLION

Bristol-Myers Squibb Foundation
Bristol-Myers Squibb Company
Hoffmann-La Roche Foundation
Hoffmann-La Roche Inc.

OVER $2.5 MILLION

The Merck Company Foundation
Merck & Co., Inc.
Merck Human Health Division
Warner-Lambert Foundation
Warner-Lambert Company
Parke-Davis

OVER $2 MILLION

Glaxo Wellcome Inc.
SmithKline Beecham Foundation
SmithKline Beecham p.l.c.
SmithKline Beecham Pharmaceuticals
SmithKline Beecham Consumer Health Care
SmithKline Beecham Clinical Laboratories
Pharmacia & Upjohn Foundation
American Home Products Corporation
Wyeth-Ayerst Laboratories
Eli Lilly and Company Foundation
Eli Lilly and Company
Pfizer Inc.

Johnson & Johnson
Advanced Care Products
Advanced Sterilization Products
Cordis Corporation
Direct Access Diagnostics
Ethicon, Inc.
Ethicon Endo-Surgery
Immunobiology Research Institute, Inc.
Indigo Medical
Janssen Pharmaceutica, Inc.
Johnson & Johnson Clinical Diagnostic
Johnson & Johnson Consumer Products Inc.
Johnson & Johnson Development Corporation
Johnson & Johnson Finance Corporation
Johnson & Johnson Health Care Systems, Inc.
Johnson & Johnson Medical Inc.
Johnson & Johnson - Merck Consumer Pharmaceuticals Inc.
Johnson & Johnson Professional, Inc.
LifeScan, Inc.
McNeil Consumer Products Company
McNeil Specialty Products Company
Neutrogena Inc.
Noramco, Inc.
Ortho Biotech, Inc.
Ortho Clinical Diagnostics, Inc.
Ortho Dermatological
Ortho McNeil Pharmaceutical
Personal Products Company
R. W. Johnson Pharmaceutical Research Institute
Therakos, Inc.
Vistakon
Johnson & Johnson Vision Products, Inc.
OVER $1 MILLION
Novartis Pharmaceuticals Corporation
Searle
Searle Pharmaceutical Group
Hoechst Marion Roussel Inc.
Schering-Plough Foundation, Inc.
Schering-Plough Corporation
Zeneca Pharmaceuticals

OVER $500,000
Sanofi Pharmaceuticals, Inc.
Bayer Corporation
Boehringer Ingelheim Corporation
Boehringer Ingelheim Pharmaceuticals, Inc.

OVER $250,000
The Procter & Gamble Company
Rhone-Poulenc Rorer Inc.

OVER $100,000
Amgen Inc.
3M Pharmaceuticals

$100,000 (AND UNDER)
Knoll Pharmaceutical Company
Organon Inc.
Astra USA, Inc.
Pasteur Merieux Connaught
Alza Corporation
Genentech, Inc.
Yamanouchi U.S.A. Inc.
Solvay Pharmaceuticals Inc.
B.F. Ascher & Company, Inc.

PhRMA ASSOCIATES AND RESEARCH AFFILIATES
AAI
American Medical Association
Clark-O’Neill, Inc.
Corbett Healthconnect
IMS America Ltd.
Kelly/Waldron and Company
Klemtner Advertising, Inc.
Lowe McAdams Healthcare
Medical Economics
Medicus Group International, Inc
NDC Health Information Services
Scott-Levin Associates
Sadler & Hennessey

*Aggregate contributions

1997 Benefactors

PhRMA MEMBER COMPANIES AND COMPANY FOUNDATIONS

$160,000 AND OVER
Bristol-Myers Squibb Foundation
Bristol-Myers Squibb Company

$125,000 AND OVER
Johnson & Johnson
Advanced Care Products
Advanced Sterilization Products
Cordis Corporation

Direct Access Diagnostics
Ethicon, Inc.
Ethicon Endo-Surgery
Immunobiology Research Institute, Inc.
Indigo Medical
Janssen Pharmaceutica, Inc.
Johnson & Johnson Clinical Diagnostics
Johnson & Johnson Consumer Products Inc.
Johnson & Johnson Development Corporation
Johnson & Johnson Finance Corporation
Johnson & Johnson Health Care Systems, Inc
Johnson & Johnson Medical, Inc.
$100,000 AND OVER
American Home Products Corporation
Hoffmann-La Roche Foundation
Pfizer Inc.
Zeneca Pharmaceuticals

$75,000 AND OVER
Hoechst Marion Roussel Inc.
Eli Lilly and Company Foundation
Eli Lilly and Company
SmithKline Beecham Foundation
SmithKline Beecham p.L.C.
SmithKline Beecham Pharmaceuticals
SmithKline Beecham Consumer Health Care
SmithKline Beecham Clinical Laboratories
Warner-Lambert Foundation
Warner-Lambert Company

$50,000 AND OVER
Glaxo Wellcome, Inc.
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Pharmacia & Upjohn Foundation
Schering-Plough Foundation, Inc.
Schering-Plough Corporation

$40,000 AND OVER
Amgen Inc.
Boehringer Ingelheim Corporation
Boehringer Ingelheim Pharmaceuticals, Inc.

$30,000 AND OVER
Bayer Corporation
The Procter & Gamble Company

$10,000 AND OVER
Rhone-Poulenc Rorer, Inc.
Sanofi Pharmaceuticals, Inc.
Searle
Yamanouchi U.S.A. Inc.

$4,000 AND OVER
Alza Corporation
Organon Inc.

$3,000 (AND UNDER)
B.F. Asher & Company, Inc.
Purdue Frederick Company

PHRMA ASSOCIATES AND RESEARCH AFFILIATES
American Medical Association
Corbett Healthconnect
Kelly/Waldron and Company
Medical Economics
NDC Health Information Services
Scott-Levin
Sudler & Hennessey
Special thanks go to all the following companies and individuals who have come alongside the Foundation by participating in the Awards in Excellence Gala

ABB Industrial Systems Inc.
American Home Products Corporation
Bayer Corporation
BF Goodrich
Burns & Roe Process Group
Centeon
Custom Metalcraft Inc.
Daichi Pharmaceutical Corporation
William R. Darrow, M.D., Ph.D.
Schering-Plough Research Institute
Walter Dixon, Ph.D.
University of Kansas
Domino Anjet
DT Industries
Elsevier Science Inc.
Excerpta Medica Inc.
FDC Reports
Fisher-Rosemount
Gebo Corporation
Geneses Reports
Greater Philadelphia First
Gusmer Enterprises
Perry V. Halushka, M.D., Ph.D.
Medical University of South Carolina
Health Care Congress Board
Ing K. Ho, Ph.D.
University of Mississippi Medical Center
Hoechst Marion Roussel
Hoffmann-La Roche Inc.
Index Manufacturing
IPX Speakers
ISPE—Society for Pharmaceutical and Medical Device Professionals
Johnson & Johnson
Kelly/Waldron and Company
Klockner-Pentaplast
KPMG Peat Marwick
Vincent Li, Ph.D.
Whitehall Robins Healthcare
Lockwood Greene
Gary M. Mawe, Ph.D.
University of Vermont
Patrick McKercher, Ph.D.
University of Maryland
Daniel Mullins, Ph.D.
University of Maryland
Moss Printing
Niro, Inc.
Novartis Pharmaceuticals Corporation
Osmonics, Inc.
Philadelphia College of Pharmaceutical Science
PECO Energy Horizon
Pfizer
Pharm Pro Magazine
Public Service Electric & Gas
Reed/Elsevier
Ed Rendell, Mayor of Philadelphia
Reed Exhibition Companies
Sepha Products
SIGMA-Tau Pharmaceuticals Inc.
SmithKline Beecham p.l.c.
The Stellar Group
STERIS Corporation
John Timoney, Police Commissioner of Philadelphia
Irwin Weiner, M.D.
SUNY Health Sciences Center at Syracuse
Valicor Associates, Inc.
Vision Quest
The West Company
Wilco AG Switzerland
Wilco USA
Wyeth-Ayerst Laboratories
Zeneca Pharmaceuticals
### PhRMA Foundation Current Programs for −1999

<table>
<thead>
<tr>
<th>Name of Program/Year of First Awards</th>
<th>Number of Awards/Budgeted Yearly/Length of Award</th>
<th>Program Budget</th>
<th>Deadline</th>
<th>Announcement Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Pharmacology Advisory Committee</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Faculty Awards in Clinical Pharmacology (1967)</td>
<td>3 budgeted/5 years</td>
<td>$360,000 total $40,000 per award per year</td>
<td>October 1</td>
<td>December 15 July 1</td>
</tr>
<tr>
<td>(2) Fellowships for Careers in Clinical Pharmacology (1973)</td>
<td>2 budgeted/2 years</td>
<td>$96,000 total $24,000 per award per year</td>
<td>October 1</td>
<td>December 15 July 1</td>
</tr>
<tr>
<td>(3) Medical Student Research Fellowships (1974-Amended 1982)</td>
<td>4 budgeted/5 months up to 24 months</td>
<td>$48,000 total $1,000 per month maximum $12,000</td>
<td>October 1</td>
<td>December 15 July 1</td>
</tr>
<tr>
<td><strong>Basic Pharmacology Advisory Committee</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(4) Faculty Awards in Basic Pharmacology/Toxicology (1973)</td>
<td>2 budgeted/2 years</td>
<td>$120,000 total $50,000 per award per year</td>
<td>September 15</td>
<td>December 15 July 1</td>
</tr>
<tr>
<td>(5) Research Starter Grants (1972)</td>
<td>11 budgeted/2 years</td>
<td>$275,000 total $12,500 per award per year</td>
<td>September 1</td>
<td>December 15 January 1</td>
</tr>
<tr>
<td>(6) Advanced Predoctoral Fellowships in Pharmacology/Toxicology (1978)</td>
<td>9 budgeted/1 or 2 years</td>
<td>$225,000 total $12,500 per award per year</td>
<td>September 15</td>
<td>December 15 January-August</td>
</tr>
<tr>
<td>(7) Faculty Development Award in Bioinformatics (1997)</td>
<td>1 budgeted/2 years</td>
<td>$60,000 total $30,000 per award per year</td>
<td>September 1</td>
<td>December 15 July 1</td>
</tr>
<tr>
<td><strong>Pharmacology Morphology Advisory Committee</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(8) Fellowships in Pharmacology-Morphology including Cell Biology (1968)</td>
<td>3 budgeted/2 years</td>
<td>$129,000 total $21,500 per award per year</td>
<td>January 15</td>
<td>March 15 July 1</td>
</tr>
<tr>
<td><strong>Pharmaceutics Advisory Committee</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(9) Advanced Predoctoral Fellowships in Pharmaceutics (1987)</td>
<td>5 budgeted/1 or 2 years</td>
<td>$125,000 total $12,500 per award per year</td>
<td>October 1</td>
<td>December 15 January-August</td>
</tr>
<tr>
<td>(10) Undergraduate Research Fellowships in Pharmaceutics (1990)</td>
<td>7 budgeted/1 year</td>
<td>$35,000 total $5,000 per award</td>
<td>October 1</td>
<td>December 15 January-July</td>
</tr>
<tr>
<td>(11) Postdoctoral Fellowships in Pharmaceutics (1992)</td>
<td>1 budgeted/1 or 2 years</td>
<td>$50,000 total $25,000 per award per year</td>
<td>October 1</td>
<td>December 15 January-December</td>
</tr>
<tr>
<td><strong>Pharmacoeconomics Advisory Committee</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12) Faculty Awards in Pharmacoeconomics (1995)</td>
<td>2 budgeted/2 years</td>
<td>$160,000 total $40,000 per award per year</td>
<td>September 1</td>
<td>December 15 July 1</td>
</tr>
</tbody>
</table>

All of the above programs will accept applications for research on drugs for rare diseases.